

DRAFT

Bay Delta Drinking Water Quality Criteria

December, 1996

CALIFORNIA URBAN WATER AGENCIES

C - 0 3 1 0 1 4

C-031014

Table of Contents

LETTER OF TRANSMITTAL	i
PREFACE	ii
EXPERT PANEL LETTER	iii
EXECUTIVE SUMMARY	ES-1
INTRODUCTION	1-1
POTENTIAL REGULATORY SCENARIO AND SCHEDULE	2-1
TREATMENT PROCESSES REQUIRED TO MEET FUTURE REGULATIONS	3-1
EVALUATION OF SOURCE WATER QUALITY AND TREATMENT EFFICIENCY	4-1
REFERENCES	R-1
LIST OF TABLES	
Table 2.1	2-3
Table 2.2	2-4
Table 3.1	3-4
Table 4.1	4-2
Table 4.2	4-7
APPENDIX A - Predictive Models for Disinfection By-Products	A-1
Table A.1.	A-3
APPENDIX B - CUWA Member Treatment Data	B-1
APPENDIX C - Delta Water Quality and Treatment Limitations for Currently Available Advanced Water Treatment Technology	C-1
Figure 1.	C-3
Figure 2.	C-4

CC:

CUWA Board of Directors
CUWA Water Quality Advisory Committee
Elaine Archibald, Consultant
Gary Bobker, The Bay Institute
Thomas Clark, K C W D
Ronnie Cohen, N R D C
David Cottingham, Counselor
David Fullerton, N H I
Richard Golb, N C W A
Robert Hultquist, D H S
David Kennedy, D W R
Gail Louis, E P A
Steven Macaulay, State Water Contractors
Bruce Mackler, E P A
Felicia Marcus, E P A
Dan Nelson, S L/D M W A
Dante Nomellini, C D W A
Erik Olson, N R D C
Roger Patterson, U S B R
Jason Peltier, C V P W A
Robert Perciasepe, US E P A
Robert Potter, D W R
Allen Short, M I D
Lester Snow, CALFED
David Spath, D H S
Phillip Wendt, D W R
Rick Woodard, D W R
Steven Yeager, D W R
Thomas Zuckerman, Attorney

Preface by California Urban Water Agencies

One objective of the CALFED Bay-Delta Program is to provide good water quality in Delta water diverted or exported to meet drinking water needs. To accomplish this, CALFED must select a long-term solution that provides a quality of source water that urban water providers can treat at reasonable cost to meet current and future federal and state health-based drinking water standards. To enable a quantitative assessment of the impact of alternative Bay-Delta solutions, specific water quality criteria must be chosen for analysis. Although there are numerous water quality constituents of concern in meeting drinking water standards, the major constituents of health concern in Delta water are pathogens (*Giardia* and *Cryptosporidium*) and disinfection by product (DBP) precursors (bromide and total organic carbon). The quality of water diverted from the Delta will bear heavily on the treatment technology which needs to be employed to meet increasingly stringent drinking water standards.

Setting water quality criteria requires knowledge about both the future regulatory setting under the Safe Drinking Water Act and the relative performance characteristics of currently available treatment technologies under a variety of actual conditions. Rather than asking its treatment experts to make this assessment, CUWA convened a panel of nationally recognized drinking water quality experts to determine the required criteria for total organic carbon (TOC) and bromide that will allow utilities treating Delta water to comply with current and probable future drinking water regulations utilizing available advanced technology. The expert panel consists of Douglas Owen, P.E. Vice President at Malcolm Pirnie, Inc., Phillippe Daniel, P.E. Associate at Camp Dresser & McKee and R. Scott Summers, PhD, Professor at the University of Cincinnati. The purpose of the expert panel report, which follows, is to identify Delta drinking water quality criteria based upon specified assumptions with which CALFED staff can evaluate the relative performance of Bay-Delta alternatives in meeting program objectives. These criteria have been developed in recognition of the interaction between source water quality, treatment efficacy and probable regulatory outcomes, as developed by the panel. This report does not represent CUWA's or any of its members endorsement of a specific regulatory outcome.

This report concludes that for currently available advanced water treatment technology to be able to meet probable future drinking water quality standards with water diverted from the Delta, the source water quality should have concentrations less than 3.0 mg/L for TOC and less than 50 µg/L for bromide. CUWA recognizes that based upon historic concentrations of these constituents measured at Clifton Court Forebay in the Delta, it is unlikely that the criteria for bromide could be met under existing conditions, even in wet years. Therefore, CALFED must carefully analyze a variety of actions within its alternatives analysis to determine which combination of actions can assure the achievement of the program's drinking water quality objective in concert with other important objectives. These actions should include at least the following:

EXECUTIVE SUMMARY

The California Urban Water Agencies (CUWA) retained the assistance of three water quality and treatment specialists who have specific expertise in the formation of disinfection by-products (DBPs). These three individuals -- the expert panel -- evaluated specific source water quality characteristics which would be necessary to permit diverted water from the San Francisco Bay/Sacramento-San Joaquin River Delta (Delta) to be used for meeting future water quality standards under defined treatment conditions. Specifically, the expert panel was charged with 1) developing an anticipated future regulatory scenario, 2) defining treatment criteria for coagulation and ozonation processes which potentially could be implemented by users of Delta water, and 3) estimating source water quality diverted from the Delta which would allow users implementing the defined treatment technologies to comply with the regulatory scenario. The source water quality characteristics were framed in the context of total organic carbon (TOC) and bromide concentrations, both constituents which have the potential to be controlled by different management strategies for the Delta.

The potential regulatory scenario includes specific limits for two organic classifications of DBPs recently proposed in rulemaking by EPA; 40 µg/L for total trihalomethanes and 30 µg/L for the sum of five haloacetic acids. In addition, a potential limit of 5 µg/L was projected for bromate, an inorganic by-product formed by the ozonation of bromide-containing waters.

The treatment criteria specified by the expert panel included: 1) the use of 40 mg/L of alum at a pH of 7.0 and possibly as low as 6.5 in the coagulation process, followed by chlorine disinfection with a chloramine residual in the distribution system, and 2) the use of ozone at specific ozone:TOC ratios followed by a chloramine residual. The chlorine and ozone disinfection criteria were proposed to meet potential 1 or 2 log *Giardia* inactivation requirements. Only the ozone disinfection strategy was considered to provide potential 1 log *Cryptosporidium* inactivation.

The expert panel used data submitted by CUWA members, available literature and ongoing research, as well as their own experience and best professional judgement to arrive at potential source water quality requirements. Available models for DBP formation were evaluated to investigate threshold DBP formation behavior and to support the initial conclusions reached by the expert panel.

Specific combinations for TOC and bromide necessary in the water diverted from the Delta can vary depending upon the treatment technology implemented and microbiological inactivation required. Further, the conservatively plausible bromate level of 5 µg/L is significant in establishing limiting bromide levels in this evaluation. The rationale for this level in this analysis ultimately may be modified by a variety of factors including allowing for trade-offs for disinfection and the formation of organically-based brominated DBPs (e.g., THMs or HAAs) or evidence of a cancer threshold for bromate (investigations underway). On the other hand, there are other potential regulatory outcomes involving 1) the regulation of individual DBPs due to the potentially more severe health effects associated with brominated compounds, 2) the addition of other regulated haloacetic acids as analytical methods develop, and 3) the concerns over reproductive defects associated with DBPs, which may lower the regulatory levels and/or peak permissible concentrations.

1.0 INTRODUCTION

The California Urban Water Agencies (CUWA) engaged the services of three water quality experts to assist in providing input to the CALFED process regarding potential management alternatives in the San Francisco Bay/Sacramento-San Joaquin River Delta (Delta). The expert panel was charged with determining the required raw water quality diverted from the Delta which would permit the effective implementation of specific drinking water treatment processes to meet potential future drinking water quality standards. The expert panel was comprised of Douglas M. Owen, P.E., Vice President at Malcolm Pirnie, Inc., Phillippe A. Daniel, P.E., Associate at Camp, Dresser & McKee, and R. Scott Summers, PhD, Professor at the University of Cincinnati.

The expert panel used data submitted by CUWA members, available literature and ongoing research, as well as their own experience and best professional judgement to arrive at potential source water quality requirements. Available models for DBP formation were evaluated to investigate threshold DBP formation behavior and to support the preliminary conclusions reached by the expert panel. This report presents the best professional judgement from this expert panel.

This report is subdivided into the following chapters:

Chapter 2 - Regulatory Scenario and Schedule

Chapter 3 - Treatment Processes to Meet Regulatory Requirements

Chapter 4 - Evaluation of Source Water Quality and Treatment Efficiency

In Chapter 2, the general trends in drinking water regulations are discussed and plausible, future regulatory criteria are presented. Treatment processes relevant to users of water diverted from the Delta are presented in Chapter 3, together with general assumptions regarding the design and application of these processes. In Chapter 4, source water quality is projected which allows the treatment processes defined in Chapter 3 to be used to meet the potential regulatory scenario presented in Chapter 2.

Other water quality contaminants, such as pesticides, herbicides, and metals, are of concern but are not likely to constrain treatment requirements as significantly as the microbial and DBP regulations, based upon occurrence in water currently diverted from the Delta.

There are other potential regulatory outcomes involving 1) the regulation of individual DBPs (rather than the groups of compounds represented by TTHM and HAA5 due to the potentially more severe health effects associated with brominated compounds, 2) the addition of other regulated HAAs (there are nine total) as analytical methods develop, and 3) the concerns over reproductive and developmental effects that may be associated with DBPs, which may lower the regulatory levels and/or the permissible peak concentration (i.e., annual averaging may no longer be the basis for determining compliance).

Further, because of the analytical difficulty in accurately characterizing microbial contamination in water, EPA is considering a treatment optimization rule, at least on an initial basis, as opposed to specific criteria for pathogenic organisms. In such a rule, "optimization" may be defined as an improvement in treatment process efficiency which minimizes the risk of microbial contamination in treated water sources.

While there are many factors that contribute to the uncertainty surrounding the anticipated regulatory scenario, it is the selected bromate level of 5 µg/L that most keenly influences the analysis. The rationale for this level (i.e., advances in detection limit, the weight of the carcinogenic evidence, the precedence for THM and HAA5 limits in Stage 2 at half the Stage 1 levels) in this analysis could ultimately be modified by a variety of factors including:

- An allowance for disinfection - bromate trade-offs (this is the World Health Organization rationale for a 25 µg/L standard). This may be critical if an inactivation requirement for *Cryptosporidium* emerges.
- A bromate versus brominated organic compound trade-off (i.e., addressing the difference between DBPs formed with ozone versus those formed with chlorine).
- Evidence of a cancer threshold for bromate (investigations underway).

Nevertheless, in the absence of more definitive direction, the panel considers a 5 µg/L value to be both prudent and plausible.

For the purposes of this evaluation, the anticipated regulatory scenario summarized in Table 2.1 was used as the basis for evaluating source water quality and treatment requirements in this report:

TABLE 2.1
POTENTIAL REGULATORY SCENARIO

Regulation	Parameter	Treatment Requirement or MCL
ESWTR	<i>Giardia</i>	Additional 1 or 2 log inactivation by disinfection, after treatment removal credit
	<i>Cryptosporidium</i>	Additional 1 log inactivation by disinfection, after treatment removal credit
D/DBP Rule	TTHMs	40 µg/L
	HAA5	30 µg/L
	Bromate	5 µg/L

2.2 REGULATORY SCHEDULE

The recently-enacted 1996 Amendments to the Safe Drinking Water Act (SDWA) have caused EPA to adopt a more ambitious schedule than EPA presented in June 1996 (see Table 2.2). The June 1996 dates were based upon a scenario in which EPA would not be “pushed” to develop an Interim ESWTR, and promulgate Stage 1 of the D/DBP Rule and the Interim ESWTR, until pathogen data were available from the Information Collection Rule (ICR).

TABLE 2.2
COMPARISON OF OLD AND NEW REGULATORY
SCHEDULE REGULATION

Regulation	Promulgation Date	
	Initial (June 1996)	Revised (August 1996)
Interim ESWTR	June 2000	November 1998
Final ESWTR	NA ⁽¹⁾	November 2000
Stage 1 D/DBP Rule	June 2000	November 1998
Stage 2 D/DBP Rule	June 2003	May 2002

Notes: (1) NA = Not available

EPA understands, however, that the Final ESWTR and Stage 2 of the D/DBP Rule, at a minimum, are linked to data availability through the ICR. Monitoring for the 18-month ICR won't begin until February 1997. Consequently, EPA is pressed between the statutory requirements and the recognition that a longer time frame would be required [e.g., promulgation (final) Stage 1 of the D/DBP Rule and Interim ESWTR in 2000 with final and effective dates for Stage 2 in 2003 and 2006 to 2008, respectively]. One possible alternative for EPA is to proceed with interim regulations for microbial and DBP control (i.e., an ESWTR focusing on "optimization" and potential elements of the Stage 1 D/DBP Rule) that would be promulgated in November 1998. In any case, both the ESWTR and Stage 2 of the D/DBP Rule would ultimately need to be finalized and become effective by the dates given in the reauthorized SDWA (November 2000 and May 2002, respectively).

Given this projected time frame, it is anticipated that the selected option for management alternatives in the Delta will be known, with construction underway, by the time the entities using Delta water need to implement required treatment technologies. Consequently, these agencies will be in a position to plan for the projected water quality from the Delta "fix" in coordination with their efforts for facility modifications to meet the regulatory requirements of the final ESWTR and Stage 2 of the D/DBP Rule.

3.0 TREATMENT PROCESSES REQUIRED TO MEET FUTURE REGULATIONS

In this chapter, general process criteria are defined to characterize specific treatment processes relevant to users of water diverted from the Delta. Source water quality is determined in Chapter 4 which permits these treatment processes to meet the regulatory scenario discussed in Chapter 2.

3.1 SELECTION OF TREATMENT PROCESSES TO BE EVALUATED

As a part of this effort, CUWA requested that the expert panel focus on those treatment processes which were considered to be the most cost-effective for simultaneously meeting the requirements of the D/DBP Rule and the ESWTR when treating water diverted from the Delta. These processes were defined as enhanced coagulation, a treatment technique proposed for Stage 1 of the D/DBP Rule, and ozone disinfection. These processes are also relevant for Stage 2 of the D/DBP Rule and were considered appropriate because they can be implemented into facilities currently owned and operated by the CUWA agencies (as well as a majority of conventional filtration facilities across the country). For example, the majority of filtration systems across the country use conventional treatment including sedimentation, which allows for increased coagulation dosages to meet proposed enhanced coagulation requirements. In addition, some CUWA facilities already use ozone disinfection. The most cost-effective option(s) for meeting potential future regulations is specific for each water purveyor, depending upon water source and quality.

There are entities which currently treat much higher quality water than that currently diverted from the Delta. These entities are able to use in-line filtration or simply disinfection without filtration to produce high quality drinking water. It should be emphasized that the determination of feasible treatment processes is dependent upon the existing source and that this evaluation is based only upon those entities currently using water diverted from the Delta as a source.

The use of post-filter granular activated carbon (GAC) adsorbers and membranes were not considered a part of this evaluation. The focus in this study was to define the source water quality needs for technologies currently applicable to large scale water treatment facilities in California. Post-filter GAC adsorbers and membranes can be at least an order of magnitude more expensive than

ozone and the feasibility of these technologies is much more uncertain based upon cost, environmental permitting constraints, and availability of residual handling alternatives. This position is shared by much of the water industry. For reference, only one treatment plant in the country at the size comparable to many of the CUWA members uses post-filter GAC as a treatment technique. There are no membrane plants in operation in the country which are used for DBP precursor removal at the facility sizes representative of the CUWA members.

It should be noted, however, that source water quality constraints from the Delta could be modified if GAC and membrane treatment ultimately were considered to be feasible treatment technologies.

3.2 GENERAL ASSUMPTIONS FOR SELECTED TREATMENT PROCESSES

3.2.1 Enhanced Coagulation

Enhanced coagulation offers the advantages of removing naturally-occurring organic material, thereby removing DBP precursors which, upon disinfection, form DBPs. As such, MCLs for TTHMs and HAA5 can be addressed by enhanced coagulation, when followed by chlorine disinfection. Upon review of the potential for DBP formation, it was determined that enhanced coagulation would only be required under conditions in which free chlorine is used for primary disinfection (pathogen inactivation), followed by chloramines for secondary disinfection to maintain a distribution system residual. Further, this treatment option is only applicable to instances in which either 1 or 2 log *Giardia* inactivation is required to demonstrate microbial control, as discussed in Chapter 2. It was assumed that *Cryptosporidium* inactivation could not be achieved by free chlorine disinfection under treatment conditions feasible for drinking water systems.

The conditions for enhanced coagulation were defined according to the specific percent removal requirements for Total Organic Carbon (TOC), as dictated in Stage 1 of the proposed D/DBP Rule (USEPA, 1994), by raw water TOC and alkalinity. Given the specific TOC removal percentages in the proposed D/DBP Rule, this translated to a projected 40 mg/L dosage of alum at a coagulation pH of 7.0, and possibly as low as 6.5. Consequently, acid addition may be required since the 40 mg/L dosage will likely only lower the pH to a value between 7.0 and 7.2. These coagulant dosages are not atypical of those currently being used by some CUWA members (e.g., Alameda County, Contra Costa, and Santa Clara Valley Water Districts), although 1) these systems

do not reduce pH with acid to improve precursor removal, and 2) many systems still prechlorinate, which cannot be used to obtain disinfection credit in the proposed D/DBP rule when using enhanced coagulation. It was assumed that a chlorine:TOC ratio of 1:1 and 60 minutes of free chlorine contact (t_{50}) would be required to achieve 1 log inactivation of *Giardia*. For 2 log *Giardia* inactivation, 120 minutes of free chlorine contact would be required.

3.2.2 Ozone Disinfection

The use of ozone disinfection offers the opportunity to meet the MCLs for TTHM and HAA5 in the potential regulatory scenario by again using chloramines as the secondary disinfectant. Therefore, additional removal of naturally-occurring organic matter may not be necessary. That is, enhanced coagulation may not have to be coupled with ozone disinfection, as long as the source water TOC is ≤ 4.0 mg/L and alkalinity is > 60 mg/L as CaCO_3 . Implementing ozone and chloramines under the Stage 1 timeframe to meet both Stage 1 and Stage 2 MCLs is one strategy for water utilities to avoid implementing enhanced coagulation when treating source waters with TOC concentrations ≤ 4.0 mg/L and alkalinity > 60 mg/L as CaCO_3 . Many entities using water diverted from the Delta, however, treat source water TOC concentrations > 4 mg/L.

For the purposes of evaluating bromate formation for 1 log *Giardia*, 2 log *Giardia*, and 1 log *Cryptosporidium* inactivation, ozone doses were projected based upon the expert panel's experience, current research, and data submitted by the CUWA members. The ratios were adjusted for pH effects (i.e., greater ozone residual persistence as pH decreases resulting in lower ozone requirements). For example, to meet 1 log *Giardia* inactivation at ambient pH, Alameda County Water District routinely requires an ozone to TOC ratio of 0.8 (ambient pH for entities using water diverted from the Delta can range from 7.5 to 9.5, a "typical" value of 7.8 was used in this analysis). At pH 7, MWD's demonstration plant results indicated roughly a 0.7 ozone:TOC ratio for achieving 2 log *Giardia* inactivation. Pilot results from the Santa Clara Valley Water District indicated that at pH 6.6 to 6.8, an ozone:TOC ratio of 0.7 to 0.9 was required for 1 log *Cryptosporidium* inactivation (the data were variable, however, and the lower pH did not necessarily correspond to lower ozone:TOC ratios for the pilot results).

Based upon the ozone dosage and inactivation data from the CUWA members and the expert panel's experience, possible ozone:TOC ratios which may be required to achieve pathogen inactivation were evaluated to take into account potential lower ozone dosages to achieve a given

inactivation under conditions of lower TOC (for example, settled water ozonation). It is important to note that CT compliance needs to be achieved continuously, and therefore an approximate 20 percent safety factor was applied to the CUWA member data. This also partially accounts for EPA's approach in setting CT values based upon 90 percentile values versus median, or 50 percentile values which are represented by the CUWA member data. The selection of ozone:TOC ratios also considered operational issues, for which it was assumed that there would be a certain "overshoot" of specific dosage targets to ensure continual CT compliance. Based upon these assumptions, bromate formation was evaluated at a range of ozone:TOC ratios and pH values, as indicated in Table 3.1.

TABLE 3.1
OZONE:TOC RATIO AND PH CONDITIONS FOR
BROMATE EVALUATION

pH	Ozone:TOC Ratios
7.8	0.8, 1.2, 1.5
7.2	0.7, 1.0, 1.3
6.8	0.6, 0.9, 1.1
6.5	0.5, 0.75, 1.0

The ozone:TOC ratios at each pH were considered to inactivate 1 log *Giardia*, 2 log *Giardia*, and 1 log *Cryptosporidium*.

4.0 EVALUATION OF SOURCE WATER QUALITY AND TREATMENT EFFICIENCY

4.1 WATER QUALITY IMPACTS AND VARIABILITY

In this section, water quality constraints are described which will allow implementation of specific treatment processes to meet potential regulatory goals. In general, the water quality constraints will be described in terms of two measurable surrogate parameters which affect DBP formation; TOC and bromide. In evaluating these water quality variables and interpreting the results, it is important to recognize that:

1. TOC is a heterogeneous mixture, and is comprised of humic and fulvic acids and other naturally-occurring organic material which varies from source to source and from location to location within a source. Consequently, TOC from different regions of the Delta will not have an identical impact on DBP formation. In this effort, it was necessary to assume that TOC could be a unifying variable for organic DBP precursor material, even given the inherent variability in the material which comprises this parameter.
2. The extent to which bromide participates in DBP reactions is dependent upon its oxidation state as well as its relative concentration with other competing oxidants (e.g., chlorine). The following analysis is not stoichiometrically-based, but rather is empirical in nature based upon measured formation rates and other data available to the Panel.
3. The formation of DBPs is dependent upon many other water quality parameters beyond TOC and bromide, alone. Some of these include temperature and pH. The Panel focused on TOC and bromide because it was assumed that management alternatives for the Delta had the opportunity to affect these variables, and therefore their control will influence subsequent DBP formation through treatment processes.

4.2 ENHANCED COAGULATION

For enhanced coagulation, source water TOC concentrations of 3, 4 and 5 mg/L and bromide concentrations of 50, 100, 150, 200 and 300 $\mu\text{g/L}$ were evaluated. As discussed in Chapter 3, an alum dose of 40 mg/L at a coagulation pH of 7.0, and possibly as low as 6.5, was projected to be required to meet the 30% TOC removal requirement for a raw water TOC of ≤ 4 mg/L and 35% TOC removal requirement for a raw water TOC of > 4 mg/L. These removals result in the treated water TOC values listed in Table 4.1. Using free chlorine as a disinfectant, a chlorine-to-TOC ratio

of 1:1 and contact times of 1 and 2 hours were projected to yield 1 and 2 log *Giardia* inactivation, respectively. To assist in assessing the TTHMs formed under these conditions, a THM formation model developed for the Metropolitan Water District of Southern California was used (Malcolm Pirnie Inc., 1993). The model was developed from 648 data observations under bench-scale conditions using various blends of water diverted from the Delta. The conditions used in this evaluation were within the experimental boundaries of the model. A more detailed description of the model is provided in Appendix A. The predicted TTHM values are summarized in Table 4.1.

TABLE 4.1

PROJECTED TTHM FORMATION USING ENHANCED COAGULATION

Water Quality			TTHM Formation (µg/L)	
Raw TOC (mg/L)	Treated TOC (mg/L)	Bromide (µg/L)	1 hr. contact	2 hr. contact
3	2.1	50	24	29
		100	27	32
		150	30	35
		200	32	38
		300	38	45
4	2.8	50	32	38
		100	35	42
		150	39	46
		200	42	50
		300	49	59
5	3.25	50	37	44
		100	40	48
		150	44	53
		200	48	57
		300	57	68

The TTHM values were compared to the data supplied by the CUWA members, those in the open literature, and with the experience of the expert panel. A summary of the data provided by the CUWA members is included in Appendix B. The available data and the expert panel's experience agreed well with values in Table 4.1.

HAAs are also formed under these reaction conditions. The Stage 2 proposed MCLs of 40 µg/L and 30 µg/L for TTHM and HAA5, respectively, yield a mass concentration TTHM-to-HAA5 ratio of 1:0.75. The DBP data supplied to the expert panel by the CUWA members indicate that the TTHM values exceed the HAA5 concentrations by greater than this ratio of 1:0.75 in 84% of the 160 cases where paired TTHM and HAA5 data were available. Other data from both research and full-scale applications in waters containing at least 50 µg/L of bromide confirm these findings (Summers, et. al., 1996, Cheng, et. al., 1995, Shukairy, et.al., 1994). Thus, it was concluded that TTHMs are the DBP of regulatory concern for this coagulation evaluation. It is important to note, however, that HAA5 represents only five of the nine bromo-chloro HAA compounds. If HAA6 or even HAA9 were to become regulated, then the controlling parameters and values could be affected.

A 20 percent safety factor on DBP production was used in determining the source water conditions which would result in the target DBP concentrations following treatment, thus a target value of 32 µg/L was used for TTHM (80% of 40 µg/L). Based upon this assumption, the following conclusions were drawn:

- 1) For a 1 log *Giardia* inactivation using free chlorine for 60 minutes following enhanced coagulation, it was projected that the following water quality conditions would permit compliance with the TTHM target concentrations in the regulatory scenario:
 - a raw water TOC concentration < 3.0 mg/L and a bromide concentration < 200 µg/L (0.20 mg/L)
 - a raw water TOC concentration < 4.0 mg/L and a bromide concentration < 50 µg/L (0.05 mg/L)

Certain combinations of raw TOC concentrations between 3 and 4 mg/L and bromide concentrations between 200 µg/L and 50 µg/L are also projected to meet the target DBP values.

- 2) For a 2 log *Giardia* inactivation using free chlorine for 120 minutes following enhanced coagulation, it was projected that a raw water TOC concentration < 3.0 mg/L and a bromide concentration < 100 µg/L (0.10 mg/L) would permit compliance with the TTHM target concentrations in the regulatory scenario.

4.3 OZONATION

The formation of bromate by ozone has come into focus only recently and the ultimate MCL for this compound is of critical importance to facilities which have bromide in their source water and are currently using, or anticipating the use of, ozone for drinking water treatment. Even small concentrations of bromide ($< 50 \mu\text{g/L}$) can result in measurable concentrations of bromate after ozonation. Therefore, the Panel carefully evaluated available data from the CUWA members, other available literature, and ongoing research on bromate formation to evaluate potential source water constraints. Based upon these data, the expert panel arrived at initial conclusions regarding potential source water bromide concentrations which would be required to limit bromate formation within the potential regulatory scenario in Chapter 2.

Unfortunately, bromate formation is strongly dependent upon the nature of the experimental system design (e.g., bench versus pilot or full-scale). In addition, bromate formation depends upon ozone dosage and residual, which is often specific for full-scale facilities, making the direct comparison of these data difficult. Therefore, a bromate model (Ozekin, 1994) was utilized to systematically evaluate the impact of ozone dose, bromide, TOC and pH on the formation of bromate and thereby supplement the available literature (Shukairy et.al., 1994), data supplied by the Alameda County Water District, Contra Costa Water District, Santa Clara Valley Water District, and Metropolitan Water District of Southern California and the expert panel's experience. The model was developed from data from several source waters including water diverted from the Delta, including results from source waters containing bromide concentrations between $70 \mu\text{g/L}$ and $440 \mu\text{g/L}$. A contact time of 12 minutes was chosen and the concentrations of TOC, bromide, ozone dose and pH were varied over representative ranges as discussed in Chapter 3. At each pH, three ozone:TOC ratios were estimated to provide the following levels of inactivation; 1 log *Giardia*, 2 log *Giardia* and 1 log *Cryptosporidium*. The dose of ozone estimated for these inactivations decreases with decreasing pH as a higher ozone residual is maintained at the lower pHs. The results of the modeling supported the initial conclusions reached by the Panel based upon the available literature and review of the CUWA data. A more detailed description of the model is provided in Appendix A.

Bromate formation is the limiting DBP (as opposed to TTHM and HAA5) for the ozone treatment and disinfection strategy specified in this evaluation. It is the opinion of the Panel that the controlling source water quality parameter for the formation of bromate, in the context of this evaluation, is bromide. It is recognized that higher concentrations of TOC will result in higher ozone dosages to achieve a given CT, and, as a result, may increase the concentration of bromate formed depending upon ozone residual, bromide concentration and potentially other parameters such as contactor design. Higher ozone dosages as a result of higher TOC also result in increased capital and operational costs for ozone treatment. Further, TOC can also be limiting to the extent that the biodegradable material, formed by the reaction between ozone and naturally-occurring organic matter (NOM), is not completely controlled through biofiltration, thereby creating an undesirable regrowth potential in the distribution system. The extent to which regrowth will be a problem is a function of the distribution system design, as well as disinfectant residuals maintained and other water quality parameters which are agency-specific. Nevertheless, sufficient data were not available to isolate the impact of TOC on bromate formation, in the absence of variation in bromide, pH and other water quality factors.

Based upon the data supplied by the CUWA members and other bromate formation studies and the model results, the expert panel concluded:

- 1) A bromate standard of 5 µg/L is very restrictive at pH values above 7. At pH 7.8 (ambient for some preozonated waters) it is projected that this standard will not be met and that a bromide level of 50 to possibly 100 µg/L would be needed to meet a bromate standard of 10 µg/L for 1 log *Giardia* inactivation.
- 2) If the ozonation pH were reduced to 6.8, then:
 - a 5 µg/L level of bromate may be achievable with 1 log *Giardia* inactivation in the bromide range of 50 to possibly 150 µg/L
 - a 10 µg/L level of bromate may be achievable with 2 log *Giardia* inactivation in the bromide range of 50 to 150 µg/L, or 1 log *Cryptosporidium* inactivation with a bromide concentration of 50 to possibly 100 µg/L.
- 3) It is projected that if the pH were depressed to 6.5, then a bromide concentration of 100 to possibly 150 µg/L could be accommodated while maintaining a bromate standard of 5 µg/L when achieving a 2 log *Giardia* inactivation. For 1 log *Cryptosporidium* inactivation, a maximum bromide concentration of 50 to possibly < 100 µg/L might be tolerated.

- 4) Limiting TOC concentrations were not estimated because of the limited availability and robustness of the data illustrating the impact of TOC on bromate formation, in the presence of bromide. It should be recognized, however, that higher TOC concentrations translate to higher ozone dosages to meet a given disinfection criterion and thereby can result in higher bromate formation. This is empirically validated in reviewing bromate formed during settled water ozonation as opposed to raw water ozonation. When TOC concentrations typically are lower at a given facility, ozone dosages to achieve a given disinfection requirement are lower, and measured bromate concentrations are lower. Lower pH in settled water also helps reduce bromate concentrations.

The expert panel recognizes that there are variations in bromate production data and therefore looked for indications relating to threshold behavior. That is, evaluating source water bromide concentrations which result in a clear increase in bromate concentrations for a given set of ozonation conditions. Given some variation in the formation of bromate reported at lower source water bromide concentrations ($< 50 \mu\text{g/L}$), the expert panel took a position of plausible conservatism.

4.3 SUMMARY

Table 4.2 summarizes projected source water quality requirements for TOC and bromide, depending upon the technology applied. In reviewing the values presented in this table, it is evident that there are various water quality constraints for TOC and bromide depending upon the technology used and the level of microbiological inactivation required. As stated previously, which technology is implemented is agency-specific, and is dependent upon a host of constraints related to cost, permitting issues and residual disposal. In some instances, lowering the ozonation pH with acid may not be feasible as a result of the inability to transport and store the chemicals necessary. Lower pH could also have an impact on the structural integrity of concrete basins, such as flocculation basins, sedimentation basins, and ozone contactors. On the other hand, ozonating at a pH of 7.0 to 7.2 may be possible without acid feed if settled water ozonation can be implemented. Existing plant hydraulic conditions and site issues affect this alternative.

TABLE 4.2

SUMMARY OF SOURCE WATER QUALITY CONSTRAINTS⁽¹⁾

TREATMENT SCENARIO / DISINFECTION STRATEGY	MICROBIAL INACTIVATION REQUIRED					
	1 Log <i>Giardia</i> Inactivation		2 Log <i>Giardia</i> Inactivation		1 Log <i>Cryptosporidium</i> Inactivation	
	TOC (mg/L)	Bromide (μ g/L)	TOC (mg/L)	Bromide (μ g/L)	TOC (mg/L)	Bromide (μ g/L)
Enhanced coagulation free chlorine/chloramines	< 3.0 or < 4.0	< 200 or < 50	< 3.0	< 100	N/A ⁽²⁾	N/A ⁽²⁾
Ozonation at pH 7.8 w/chloramines	N/E ⁽⁴⁾	N/A ⁽³⁾	N/E ⁽⁴⁾	N/A ⁽³⁾	N/E ⁽⁴⁾	N/A ⁽³⁾
Ozonation at pH 6.8 w/chloramines	N/E ⁽⁴⁾	< 150	N/E ⁽⁴⁾	< 50	N/E ⁽⁴⁾	N/A ⁽³⁾
Ozonation at pH 6.5 w/chloramines	N/E ⁽⁴⁾	< 200 to 250	N/E ⁽⁴⁾	< 100 to 150	N/E ⁽⁴⁾	< 50

- Notes:
1. Source water quality constraints are based upon achieving 40 μ g/L of TTHM, 30 μ g/L of HAA5, and 5 μ g/L of bromate using the treatment and disinfection conditions presented in Chapter 3.
 2. N/A = Not achievable. At this time, it is considered that free chlorine can not inactivate *Cryptosporidium* at dosages practical in water treatment.
 3. N/A = Not achievable. Bromide concentrations would have to be considerably less than 50 μ g/L to achieve a bromate concentration of 5 μ g/L. Data to determine the necessary bromide concentration relevant to this study were not available.
 4. N/E = Not estimated. Limiting TOC concentrations were not estimated because of the limited availability and robustness of the data illustrating the impact of TOC on bromate formation, in the presence of bromide. It should be recognized, however, that higher TOC concentrations translate to higher ozone dosages to meet a given disinfection criterion and thereby can result in higher bromate formation.

The Panel is also aware of the significance of bromate in establishing limiting bromide levels in this evaluation. There are many factors that contribute to the uncertainty surrounding the projected numbers, including relatively few studies which have evaluated bromate formation in low bromide waters (< 50 μ g/L), variations in treatment conditions which may reduce bromate formation (e.g., using both pre- and post-ozonation to reduce ozone dosages at any single location), and potentially lower CT values for ozone. It is the selected conservative (but plausible) level of 5 μ g/L, however, that most keenly influences the analysis. The rationale for this level (i.e., advances in detection limit, the weight of the carcinogenic evidence, the precedence for THM and HAA5 limits in Stage 2 at half the Stage 1 levels) in this analysis may be modified by a variety of factors including:

- An allowance for disinfection - bromate trade-offs (this is the World Health Organization rationale for a 25 μ g/L standard). This may be critical if an inactivation requirement for

Cryptosporidium emerges.

- A bromate versus brominated organic compound trade-off (i.e., addressing the difference between DBPs formed with ozone versus those formed with chlorine).
- Evidence of a cancer threshold for bromate (investigations underway).

On the other hand, there are other potential regulatory outcomes involving 1) the regulation of individual DBPs (rather than the groups of compounds represented by TTHM and HAA5) due to the potentially more severe health effects associated with brominated compounds, 2) the addition of other regulated HAAs (there are nine total) as analytical methods develop, and 3) the concerns over reproductive defects associated with DBPs, which may lower the regulatory levels and/or peak permissible concentrations (i.e., annual averaging may no longer be the basis for determining compliance).

Given this understanding, if flexibility were provided to all agencies to implement any of the technologies evaluated in this study to meet the potential future regulatory scenario, then it is projected that a TOC of < 3.0 mg/L and a bromide of < 50 µg/L in water diverted from the Delta would be necessary. The TOC value is constrained by the formation of total trihalomethanes when using of enhanced coagulation for TOC removal and free chlorine to inactivate *Giardia*. The bromide value is constrained by the formation of bromate when using ozone to inactivate *Cryptosporidium*.

REFERENCES

- Cheng, R. C. et. al., 1995. "Enhanced Coagulation : A Preliminary Evaluation," *Journal AWWA*, 87:2:91 (February, 1995).
- Malcolm Pirnie, Inc., 1993. *Bay-Delta Water Quality Modeling*, prepared for the Metropolitan Water District of Southern California, December 1993.
- Ozekin, K., 1994. *Modeling Bromate Formation During Ozonation and Assisting Its Control*. PhD Thesis, University of Colorado, 1994.
- Shukairy, H. M. et. al., 1994. "Bromide Impact on Disinfection By-Product Formation and Control: Part 1 Ozonation," *Journal AWWA*, 86:6:72 (June, 1994).
- Summers, R.S. et. al., 1996. "Assessing DBP Yield: Uniform Formation Conditions," *Journal AWWA*, 88:6:80 (June 1996).
- USEPA, 1994. National Primary Drinking Water Regulations; Disinfectants and Disinfection Byproducts; Proposed Rule. *Fed. Reg.*, 59:145:38668 (July 29, 1994).

APPENDIX A

PREDICTIVE MODELS FOR DISINFECTION BY-PRODUCTS

A.1 THM PREDICTIVE EQUATIONS

Malcolm Pirnie, Inc. (1993) undertook a study on the formation of DBPs in chlorinated waters over a wide range of TOC and bromide concentrations for the Metropolitan Water District of Southern California. A 5 by 5 matrix of discrete samples containing incremental increases in TOC and bromide concentrations were prepared and evaluated. For this study, water was synthesized using low-TOC, low bromide Sacramento River water and high-TOC agricultural drainage water. High-bromide concentrations were achieved by adding sodium bromide.

The database used in this study, consisting of more than 900 observations, was constructed based upon the results of the source water quality monitoring program and the chlorination experiments from the 5 by 5 matrix. One portion of the database represented THM formation in jar-treated waters and another portion represented THM formation in 0.45 µm membrane filtered raw water.

Three sets of THM predictive equations were developed during this study using a non-linear power function format including total organic carbon (TOC), ultraviolet absorbance at 254 nm (UV-254), chlorine dose, bromide concentration, reaction time, temperature and pH as independent variables. The final TTHM predictive equation was based upon a portion of the database representing THM formation in 0.45 µm membrane filtered raw water (approximately 650 observations). Predictive capabilities of this equation was compared with THM formation in the jar-treated water (approximately 250 observations). The final TTHM equation developed was:

$$\text{TTHM} = 7.21 \text{ TOC}^{0.004} \text{ UV254}^{0.534} (\text{ClDOSE} - 7.6 * \text{NH}_3\text{-N})^{0.224} \text{ TIME}^{0.255} (\text{Br} + 1)^{2.01} (\text{pH} - 2.6)^{0.719} \text{ TEMP}^{0.480}$$

$$[r^2 = 0.96, F = 2010, p < 0.001]$$

This equation was developed at TOC concentrations ranging between 1.1 and 7.6 mg/L, bromide between 10 and 800 µg/L, contact times between 1 and 48 hours, and chlorine doses between 1.0 to 16.4 mg/L. The values for UV-254 to be input into the TTHM equation were predicted using a relationship between TOC and UV-254 developed in the study as follows:

$$\text{UV-254} = -0.0224 + (0.0374)(\text{TOC})$$

$$(r^2 = 0.92)$$

Using free chlorine as a disinfectant, a chlorine-to-TOC ratio of 1:1 and contact times of 1 and 2 hours were projected to yield 1 and 2 log *Giardia* inactivation, respectively. A temperature of 20 ° C and pH of 7 was also input to this equation to yield the values in Table 4.1 in the body of this report.

A.2 BROMATE PREDICTIVE EQUATION

The bromate model of Ozekin and Amy (Ozekin, 1994) was utilized to systematically evaluate the impact of ozone dose, bromide, DOC and pH on the formation of bromate. The model was developed from data from several source waters including waters diverted from the Delta. Source water bromide concentrations ranged between 70 and 440 µg/L with bromate concentrations ranging between 2 and 314 µg/L.

The model used has the following form:

$$\text{BrO}_3 = 1.63 \times 10^{-6} \text{ DOC}^{-1.26} \text{ pH}^{5.82} (\text{O}_3 \text{ dose})^{1.57} \text{ Br}^{0.73} \text{ time}^{0.28}$$

A contact time of 12 minutes was chosen and the concentrations of DOC, bromide, ozone dose and pH were varied over a representative range as input to the above equation. Temperature was held constant at 20 ° C. The bromate formation results are shown in Table A.1.

It is important to note that the model was only used to support conclusions reached by the expert panel prior to using the model. The bromate model was evaluated to investigate threshold behavior regarding formation at specific levels and to support the initial conclusions reached by the expert panel. The results of the modeling should not be overemphasized. The results of the modeling supported the initial conclusions reached by the Panel based upon the available literature and review of the CUWA data.

TABLE A.1
PREDICTED BROMATE FORMATION

TOC (mg/L)	Br (µg/L)	O3:TOC at pH 7.8			O3:TOC at pH 7.2			O3:TOC at pH 6.8			O3:TOC at pH 6.5		
		0.8 ⁽¹⁾	1.2 ⁽²⁾	1.5 ⁽³⁾	0.7 ⁽¹⁾	1 ⁽²⁾	1.3 ⁽³⁾	0.6 ⁽¹⁾	0.9 ⁽²⁾	1.1 ⁽³⁾	0.5 ⁽¹⁾	0.75 ⁽²⁾	1 ⁽³⁾
2	50	8	15	21	4	7	10	2	4	6	1	2	4
	100	13	24	34	7	11	17	4	7	10	2	4	6
	150	17	33	46	9	15	23	5	9	13	3	5	8
	200	21	40	57	11	19	29	6	12	16	4	7	10
2.5	50	8	16	22	4	7	11	2	4	6	1	3	4
	100	14	26	37	7	12	18	4	7	10	2	4	7
	150	18	35	50	9	16	25	5	10	14	3	6	9
	200	23	43	61	12	20	31	7	12	17	4	7	11
3	50	9	17	23	4	8	12	3	5	6	1	3	4
	100	15	27	39	7	13	20	4	8	11	2	5	7
	150	20	37	52	10	17	26	6	11	14	3	6	10
	200	24	46	65	12	21	32	7	13	18	4	8	12
4	50	10	18	26	5	9	13	3	5	7	2	3	5
	100	16	30	43	8	14	21	5	9	12	3	5	8
	150	21	40	57	11	19	29	6	12	16	4	7	10
	200	26	50	71	13	23	35	8	14	20	4	8	13

- Notes: 1. Ozone:TOC ratio anticipated to achieve 1 log *Giardia* inactivation.
2. Ozone:TOC ratio anticipated to achieve 2 log *Giardia* inactivation.
3. Ozone:TOC ratio anticipated to achieve 1 log *Cryptosporidium* inactivation.

APPENDIX B

CUWA MEMBER TREATMENT DATA

Data was provided by the CUWA members, including those resulting from the operation of their treatment facilities as well as bench and pilot studies. There are variations in these data which are unique to each treatment system. For example, some systems supplied data representing ozonation of only raw water, while others supplied data with both pre- and post-ozonation. The expert panel recognizes that there are unique aspects of process operation which can affect the ultimate formation of DBPs. For this study, however, the expert panel defined "unifying criteria" in Chapter 3 for enhanced coagulation and ozone which allow a comparison of these processes and a systematic method by which to evaluate the impact of water quality constraints on DBP formation. This appendix contains the data supplied by the CUWA members.

bromate

Contra Costa WD						
Randall-Bold WTP						
Sample	Bromate	Chloride	Bromide			
Date	(measured)	(daily avg)	(estimated)			
	(µg/L)	(mg/L)	(mg/L)			
2/23/93	<0.5	72	0.22			
4/6/93	<1.4	89	0.27			
5/21/93	10	55	0.17			
6/15/93	6	30	<0.1			
8/18/93	6	25	<0.1			
10/5/93	10.3	60	0.18			
11/17/93	30.4	142	0.43			
1/4/94	1.5	70	0.21			
2/9/94	4.6	70	0.21			
3/1/94	2.6	55	0.17			
4/5/94	7.3	77	0.23			
5/10/94	<3	57	0.17			
7/12/94	<5	112	0.34			
8/9/94	<5	133	0.4			
10/4/94	51	158	0.48			
10/10/94	33	118	0.36			
11/1/94	15	150	0.45			
12/6/94	13	162	0.49			
1/10/95	5.7	94	0.28			
2/14/95	17	60	0.18			
3/14/95	7.6	35	0.11			
4/4/95	18	105	0.32			
6/13/95	<5	40	0.12			
7/11/95	21	32	0.1			
8/8/95	7.8	32	0.1			
9/19/95	<5	16	<0.1			
10/3/95	<5	14	<0.1			
11/7/95	<5	16	<0.1			
12/12/95	<5	23	<0.1			
2/6/96	<5	40	0.12			
3/5/96	<5	117	0.35			
Note:	Ozone	dose	currently	optimized	for	coagulation,
	not	bromate	production.			
Conservative	ozone	doses:	pre-ozone	2.5-3 ppm	(raw water	
			post-ozone	1ppm	(filtered)	
Plant CT operating	from 2-5					

C - 0 3 1 0 4 1

Utility ID:	EBMUD	(ACMD, CCMO, EBMUD, MWD, SCVWD)											
1. Study ID:	EBMUD Alternate Source Study	(Optimization Study WRS, etc.)											
2. Source water:	(American) River	(River, lake, groundwater, etc.)											
3. Source water ID:		(State Project water, etc.)											
5. Describe point of reference for which water quality data are being supplied, i.e. upstream and downstream of City of Sacramento combined sewage discharge, etc.													
Nimbus Dam, American River													
Monitoring data on seasonal changes in plant raw source water quality, use upstream column.													
WATER QUALITY DATA: RAW													
Date	Time	TOC (mg/L)	Alkalinity (mg/L as CaCO3)	Hardness (mg/L as CaCO3)	Bromide (mg/L)	Ammonia (mg NH3-N/L)	Chloride (mg Cl-/L)	TDS (mg/L)	Turbidity (NTU)	pH	Temperature (deg C)	Microbial Parameters	
		Upst.	Down.	Upst.	Down.	Upst.	Down.	Upst.	Down.	Upst.	Down.	Total Coliforms (#/100mL)	Fecal Coliforms (#/100mL)
1/17/09		2.4	3.2	3.3	<0.005	0.009	4	59	1.8	7.7	6	26	11
2/14/09		1.6	3.1	3.2	<0.03	0.01	5	60	0.98	7.6	6	50	11
3/13/09		2.8	3.3	3.5	<0.02	0.01	4	64	3.5	7.6	11	430	140
4/17/09		1.6	3.2	2.8	<0.05	0.016	3	53	2.3	6.1	15	600	500
5/15/09		1.9	2.4	2.5	<0.05	<0.005	3	50	1.5	7.6	18	210	30
6/18/09		1.9	2.4	2.2	<0.05	0.04	2	45	1.1	7.6	18	170	30
6/18/09		2.3	2.3	120			13	47	1.2			170	60
6/18/09		1.4	2.1	2.2	<0.03	<0.005	2	46	0.2	7.5	24	500	130
7/17/09		3.5	2.4	2.1	<0.05	0.005	4	44	0.62	7.4	24.5	1500	300
8/25/09		1.4	2.1	2.0	<0.01	<0.005	2	41	0.45	7.5	20	300	80
11/13/09		1.7	2.1	2.1	<0.01	<0.005	2	41	1.1	7.4	16	80	130
12/11/09		1.3	2.9	2.4	<0.01	0.01	2	47	2.5	7.4	11	1100	800
12/11/09		1.3	2.3	2.4	<0.01	<0.005	2	48	1.3	7.6	9	2200	2200
1/22/09		1.6	2.5	2.6	<0.02	0.007	4	50	5.5	7.7	6	110	110
3/20/09		1.3	3.6	3.2	0.01		5	57	1.6	7.8	11.5	800	300
3/20/09		1.2	3.1	2.9	<0.01	<0.005	4	53	0.57	7.8	17.5	17	4
6/25/09		1.3	2.7	2.7	<0.05	0.03	3	54	0.64			80	50
6/25/09		1.3			<0.01		4	46	0.38	7.5	17.5	200	80
7/16/09		1.4			0.02		2	43	0.5			11	
8/20/09		1.4			0.01		2	39	0.95			80	30
8/17/09		1.5	2.1	1.8	0.11		2	40	0.77	7.4	20	50	70
10/15/09		1.6	2.2	2.0	<0.01		4	43	0.8			170	
11/26/09		1.5			<0.01		4	43	0.84			500	
12/17/09		1.2	2.5	2.1	<0.01		3	34	1.3	7.6		70	
1/7/09		1.3	2.2	2.2	0.02	0.01	4	47	1.9			50	
2/11/09		1.7	3.0	3.2	0.01	0.01	6	50	4.1	7.2	13	110	110
3/11/09		2.3	2.7	3.2	0.01	0.08	4	58	3.4	7.6	12	1700	500
4/8/09		3.2	3.6	3.8	0.01	0.01	4	66		6.6	18	50	23
5/20/09		1.9	3.2	3.2	<0.02		2	59	1.6	8.2	19.5	600	500
6/17/09		1.8	2.6	2.6	<0.01		3	51	1.8	7.6	21.5	70	11
6/17/09		1.3	2.8	2.5	<0.01		2	50	1.2	7.8	20.5	90	30
7/8/09		1.7	3.2	3.1			2	51	1.5	8.4		500	80
7/8/09		1.5	2.7	2.3	<0.01		3	46	1.6			50	17
8/19/09		1.6	2.6	2.4			3	49	1.1	7.8	23.5	60	23
8/19/09			2.4	2.2	<0.01		4	55	0.6	7.6	24	350	30
8/19/09		1.6	2.5	2.1	0.07	0.02	3	45	1.1	7.4	20.5	110	80
10/15/09		1.4	2.7	2.5	<0.01	0.01	3	48	1.2	7.6	15	130	23
11/18/09			2.7	2.5	0.1								
12/18/09		1.7	2.6	2.3	<0.05		2	44	0.79	7.6	11	70	70

Utility ID:	ACWD		(ACWD, CCWD, EBMUD, MWD, SCVWD)														
1. Study ID:	(Optimization Study 9/95, etc.)																
2. Source water:	(River, lake, groundwater, etc.)																
3. Source water ID:	(State Project water, blend of....., etc.)																
5. Describe level of study:	Bench-scale	In this data sheet, "Filt." refers to data collected															
(Indicate with an 'X')	Pilot-scale	after coagulation, flocculation, sedimentation, and															
	Full-scale	filtration.															
6. Indicate with an 'X' if data reported as "Filt." are from samples collected after sedimentation only:																	
	or after sedimentation and filtration:																
WATER QUALITY DATA: CONVENTIONAL																	
Date	Time	TOC (mg/L)		UV-254 (1/cm)		Bromide (µg/L)		Turbidity (NTU)		Temperature (deg. C)		Disinfection By-products					
		Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.	TTHM (µg/L)		HAA5 (µg/L)		HAA6 (µg/L)	
												Raw	Filt.	Raw	Filt.	Raw	Filt.
5/30/95		4.3	2.7					16.2		65.4							
6/5/95		4.3	2.0			40.0		29.0		65.9		28.9					
6/13/95		3.6	1.8			42.0		14.1		67.3		40.2					
6/20/95		3.5	1.9			60.0		15.6		66.3		44.0		48.0			
6/27/95		3.8	2.0			80.0		13.4		76.7		49.6					
7/4/95		4.2	2.3					17.4		73.3		45.2					
7/11/95		4.1	2.1			68.0		23.0		72.3		43.0					
7/18/95		3.8	1.9			50.0		19.5		73.5		45.9					
7/25/95			2.4			72.0		21.2		72.6		48.0					
8/1/95		4.1	2.2			65.0		13.3		78.3		48.0					
8/8/95		3.6	1.9			60.0		11.5		75.2		49.8					
8/15/95		3.1	2.0			60.0		11.4		77.0		58.9					
8/22/95		3.2	2.2			55.0		10.6		75.6		58.9					
8/29/95						50.0		11.5		71.2							
9/5/95		3.4	2.0			81.0	<20	12.5		70.5		61.1		37.0		44.0	
9/12/95		4.1	3.3			42.0	12.0	2.3		68.9		86.9					
9/19/95		4.0	3.2			50.0	<20	2.2		68.4		85.9		58.0		65.0	
9/26/95		4.0	2.8			53.0	10.0	8.3		67.9							
10/3/95		4.1	2.8			49.0	17.0	5.0		64.1		55.4		43.0		49.0	
10/10/95		4.3	3.0			44.0	<40	4.4		62.6		72.0					
10/17/95		4.2				43.0		6.6		63.0							
10/24/95		3.9	2.8			47.0	14.0	4.3		61.9							
10/31/95		3.8	2.5			45.0	12.0	6.5		61.7		58.6		35.0		40.0	
11/7/95		3.8	2.6	0.19	0.07	47.0	13.0	5.3		59.9		72.1					
11/14/95		4.3	3.1	0.18		39.0	12.0							46.0		52.0	
11/21/95		3.4	3.3	0.19	0.10	42.0	16.0										
11/28/95				0.14	0.10	86.0	16.0					55.5		23.0		28.0	
12/5/95		4.4	3.4	0.13	0.09			1.6		58.5		73.1					
12/12/95		4.6	4.0	0.12	0.08	39.0	<20	2.2		58.0				56.0		62.0	
12/19/95		4.7	3.7	0.14	0.10	38.0	<20	3.9		55.8		73.3					
12/26/95		3.1	2.0	0.12	0.09	97.0	24.0	7.6		52.5				31.0		38.0	
1/2/96		3.3	2.1	0.13	0.09	150	36.0	3.6		53.8		64.6					
1/9/96		6.4	3.7	0.24	0.10	110	31.0	4.8		52.7		75.2		54.0		63.0	
1/16/96		6.4	3.5	0.27	0.11	87	24.0	4.0		51.4		80.0					
1/23/96		3.0	2.4	0.18	0.16			9.3		50.7							
1/30/96		3.5	3.2	0.20	0.10			20.0		51.4		77.8					
2/6/96		5.6	3.6	0.20	0.11							75.0					
2/13/96		5.6	3.6	0.17	0.08							76.1					
2/20/96		5.8	3.6	0.13	0.31							88.0					
2/27/96		5.8	3.0	0.20	0.11							72.8					
3/5/96		0.0	3.1	0.22	0.09		14.0					80.7		54.0		57.0	
3/12/96		5.6	3.1	0.21	0.10		<20										
3/19/96		5.5	3.4	0.22	0.10		<20					61.3		49.0		52.0	
3/26/96		5.3	3.1	0.21	0.09		14.0					81.3					
4/2/96				0.20	0.09							57.2		31.0		38.0	
4/9/96				0.21	0.08							94.7					
4/16/96		4.4	3.0	0.20	0.10		<10.0							59.0		68.0	
4/23/96		4.2	2.8	0.21	0.09		29.0					71.4					
4/30/96			2.4		0.09		34.0					76.7		41.0		52.0	
5/7/96		3.7	2.6	0.20	0.09		41.0					73.3					
5/14/96		3.6	2.8	0.21	0.09		45.0					85.0		43.0		55.0	
5/21/96					0.09												
5/28/96		3.8	2.1	0.22			20.4					52.3		34.0		41.0	
6/4/96		3.6	2.3	0.22	0.08		24.6					70.4					
6/11/96			1.9		0.08		17.2					80.1		38.0		43.0	
6/18/96			1.8	0.19	0.08		10.6					53.9					
6/25/96			1.9		0.08		25.2					43.9					
7/2/96		3.2	2.0				20.4					64.8					
7/9/96							13.7										

[illegible]

Utility ID:																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																			</
-------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	----

Utility ID:	ACWD				[ACWD, CCWD, EBMUD, MWD, SCWD]					
1. Study ID:	Enh. Coagulation (from EC study data)				[Optimization Study 9/95, etc.]					
2. Source water:	River				[River, lake, groundwater, etc.]					
3. Source water ID:	South Bay Aqueduct				[State Project water, blend of..., etc.]					
5. Describe level of study:	Bench-scale				In this data sheet, "Filt." refers to data collected after coagulation, flocculation, sedimentation, and filtration.					
(Indicate with an 'X')	Pilot-scale									
	Full-scale									
6. Indicate with an 'X' if data reported as "Filt." are from samples collected after sedimentation ONLY:					or after sedimentation AND filtration:					
					X					
WATER QUALITY DATA: CONVENTIONAL										
Date	Time	TOC (mg/L)		Alkalinity (mg/L as CaCO ₃)		Hardness (mg/L as CaCO ₃)		Turbidity (NTU)	pH	Temperature (deg. C)
		Raw	Filt.	Raw	Filt.	Total	Calcium	Raw	Filt.	Raw
			(settled)						(settled)	
		3.2	1.9	104		132		11.5	2.2	7.7
		3.1	2.1	105		118		6.0167	1.1	8.1
		3.7	2.8	112		120		4.65	1.7	7.6
		4.0	2.7	127		150		2.1667	0.8	7.9
		3.6	2.6	128		144		2.167	2.3	7.9
		5.8	4.0	152		142		24.333	6.9	7.9
		5.6	4.2	158		144		11.933	4.4	8.4
		5.8	4.1	127		134		8.2833	2.4	8.1
		6.1	3.8	110		144		17.117	3.9	8.2
		5.8	3.6	102		120		21.233	2.6	8.3
		6.1	3.3	117		134		76.667	13.4	8
		5.9	4.3	96		116		13.633	2.7	8.6
		5.6	4.0	87		124		8.9667	2.6	8.7
		5.8	4.2	98		118		11.55	3.4	8.5
		5.3	3.7	105		126		10.783	3.3	8.3
		5.1	3.7	78		108		8.6833	2.5	7.9
		3.2	2.00	104		132		11.5	2.97	7.7
		3.1	2.40	105		118		6.0167	1.53	8.1
		3.7	3.10	112		120		4.65	1.88	7.6
		4.0	2.80	127		150		2.1667	1.09	7.9
		3.6	2.60	128		144		2.167	1.00	7.9
		5.8	3.70	152		142		24.333	3.02	7.9
		5.6	4.20	158		144		11.933	2.98	8.4
		5.8	4.10	127		134		8.2833	2.18	8.1
		6.1	3.50	110		144		17.117	2.68	8.2
		5.8	3.30	102		120		21.233	3.65	8.3
		6.1	3.30	117		134		76.667	4.98	8
		5.9	4.00	96		116		13.633	2.39	8.6
		5.6	3.60	87		124		8.9667	2.18	8.7
		5.8	3.70	98		118		11.55	2.92	8.5
		5.3	3.50	105		126		10.783	2.30	8.3
		5.1	3.40	78		108		8.6833	2.02	7.9

								</		

Utility ID:	CCWD: Bollman WTP		(ACWD, CCWD, EBMUD, MWD, SCWWD)																						
1. Study ID:	Historical data 7/1/95-6/30/96		(Optimization Study 9/95, etc.)		4. If blended source water indicate sources and proportions:																				
2. Source water:	Delta - Mallard Slough/Rock Slough		(River, lake, groundwater, etc.)		Source %																				
3. Source water ID:	Central Valley Project Water		(State Project water, blend of..., etc.)																						
5. Describe level of study:	Bench-scale		In this data sheet, "Filt." refers to data collected after coagulation, flocculation, sedimentation, and filtration.																						
(Indicate with an 'X')	Pilot-scale																								
	X Full-scale																								
6. Indicate with an 'X' if data reported as "Filt." are from samples collected after sedimentation only;																									
					or after sedimentation and filtration: X																				
WATER QUALITY DATA: CONVENTIONAL																									
Date	Time	TOC (mg/L)		UV-254 (1/cm)		Alkalinity (mg/L as CaCO3)				Hardness (mg/L as CaCO3)				Bromide (µg/L)		Ammonia (mg NH3-N/L)		Chloride (mg Cl-/L)		TDS (mg/L)		Turbidity (NTU)		pH (°)	
		Raw	Filt.	Raw	Filt.	Raw	Filt.	Total		Calcium		Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.		
								Raw	Filt.	Raw	Filt.														
Jul-95						43.9	44.4	47.8	47.9			<0.1	<0.1	<0.1	0.32	21.3	21.3	90	120	3	0.05	7.8	8.8		
Aug-95						42.3	42	47.1	46.6			<0.1	<0.1			20.3	21.3		115	2.4	0.05	8.1	8.9		
Sep-95						47.2	48.3	48.4	47.9			<0.1	<0.1			16.1	16.3		110	2.4	0.05	8	9		
Oct-95						52.4	54.2	53.1	54.8			<0.1	<0.1	<0.1	0.25	17.7	18	90	113	3.1	0.05	8.2	9		
Nov-95						52.3	51.7	55.1	55.4			<0.1	<0.1			20	20.4		120	5	0.05	8.4	8.9		
Dec-95						54.7	55.5	62	61.3			<0.1	<0.1			22.3	22.4		130	5.7	0.05	8	8.9		
Jan-96						63.2	60.5	71.8	71.5			<0.1	<0.1	<0.1	0.28	29.6	29.8	130	160	6.8	0.05	8.5	9		
Feb-96						67.7	67.4	78	75.7			<0.1	<0.1			33.5	32		195	5.1	0.05	7.8	8.7		
Mar-96						64.5	63.8	77.5	76.3			<0.1	<0.1			34.3	34.3		195	5.5	0.05	8	8.9		
Apr-96						63.8	64.3	84.3	82			<0.1	<0.1	<0.1	0.18	36.9	37.5	160	193	5	0.05	8	8.9		
May-96						62.5	62.4	88.2	88.8			<0.1	<0.1			44.8	45.7		210	5.4	0.05	8.2	8.8		
Jun-96						54.6	55.8	71.5	73.8			<0.1	<0.1			35.6	36.5		170	6.4	0.05	8.1	8.9		

Temperature (deg. C)		Bromate (µg/L)		Coliforms				Giardia		Crypto.		Viruses		HPC		Indicate disinfectants used with an 'X'		Chlorine dose (mg Cl ₂ /L)		Ammonia dose (mg NH ₃ -N/L)		Incubation time (h)	
Raw	Filt.	Raw	Filt.	Total (#/100mL)	Filt.	Fecal (#/100mL)	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.	chlorine	chloramine			chlorine	chloramine		
24.8				44	0	7		0	0	0	0			960	0								
25.2				6	0	3								1750	0								
23.7				8	0	14								410	0								
20.8				42	0	5								480	0								
18.1				29	0	27								3600	0								
14.3				21	0	3		0	0	0	0			13700	0								
12.1				26	0	5		0	0	0	0			2100	0								
14				31	0	16		<5.3		<5.3				160	0								
15.1				700	0	10		0	0	0				63700	0								
17.8				33	0	5		0	0	0				880	0								
20.5				37	0	9		0	0	0	<1			1500	0								
21.8				7	0	1								20400	10								

Page 3

[illegible]

Utility ID:	MWD	IACWD, CCWD, EBMUD, MWD, SCWMD									
1. Study ID:	J&T TSS - range of %SPW/CRW	Indicate coagulant studied:									
2. Source water:	Source (River, lake, groundwater, etc.)	1) Alum 2) Polymer									
3. Source water ID:	SPW, CRW (Slime Pledge water, Bend Oil, ... etc.)	3) Sometimes 2) mg/L polymer									
4. Describe level of study:	X Batch-scale Pilot-scale Full-scale	Doses include usually 3 (sometimes 2) mg/L polymer									
5. Indicate with an 'X' if data reported as "Full" are from samples collected after sedimentation only, or after sedimentation and filtration:	In this data sheet, "Full" refers to data collected after coagulation, flocculation, sedimentation, and filtration.	X 60 min settling time									
WATER QUALITY DATA: CONVENTIONAL											
Study ID	Water	TOC (mg/L)	UV-254 (1/cm)	Alkalinity (mg/L as CaCO3)	Turbidity (NTU)	pH	Coagulant ID	Dose	Coag. pH		
	% CRW	% SPW	Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.	
MWDABU	100	2.42	2.43	0.023	123	0.74	0.74	\$0.0	1	8.06	
MWDABU	100	2.42	2.33	0.025	0.019	123	0.74	0.74	\$0.0	1	7.71
MWDABU	100	2.42	2.27	0.025	0.035	123	0.74	0.54	\$0.0	1	7.44
MWDABU	100	2.42	2.17	0.025	0.035	123	0.74	0.64	\$0.0	1	7.34
MWDABU	100	2.42	2.02	0.023	0.031	123	0.74	0.63	\$0.0	1	7.24
MWDABU	100	2.42	1.93	0.025	0.019	123	0.74	0.74	\$0.0	1	6.93
MWDABU	100	2.42	1.86	0.025	0.034	123	0.74	0.83	\$0.0	1	6.81
MWDABU	100	2.42	1.88	0.023	0.034	123	0.74	0.87	\$0.0	1	6.77
MWDABU	100	2.42	2.20	0.019	0.019	123	0.65	0.62	\$0.0	0	6.29
MWDABU	100	2.25	2.12	0.019	0.011	132	0.65	0.56	\$0.0	1	7.88
MWDABU	100	2.25	1.97	0.016	0.011	132	0.65	0.51	\$0.0	1	7.67
MWDABU	100	2.25	1.97	0.016	0.010	133	0.65	0.47	\$0.0	1	7.43
MWDABU	100	2.25	1.83	0.013	0.007	133	0.65	0.62	\$0.0	1	7.33
MWDABU	100	2.25	1.67	0.017	0.014	132	0.65	0.74	\$0.0	1	7.24
MWDABU	100	2.25	1.48	0.017	0.014	132	0.65	0.74	\$0.0	1	7.24
MWDABU	100	2.25	1.67	0.019	0.011	132	0.65	0.74	\$0.0	1	6.93
MWDABU	100	2.25	1.61	0.019	0.012	132	0.65	0.74	\$0.0	1	6.81
MWDABU	100	2.25	1.56	0.019	0.011	132	0.65	0.74	\$0.0	1	6.75
MWDABU	100	2.25	1.52	0.015	0.010	132	0.65	0.74	\$0.0	1	6.67
MWDABU	100	2.25	1.47	0.011	0.010	132	0.65	0.74	\$0.0	1	6.57
MWDABU	100	2.26	2.41	0.016	0.018	132	0.62	0.74	\$0.0	1	8.15
MWDABU	100	2.26	2.28	0.016	0.013	132	0.62	0.74	\$0.0	1	7.88
MWDABU	100	2.26	2.11	0.016	0.012	132	0.62	0.74	\$0.0	1	7.71
MWDABU	100	2.26	1.96	0.016	0.012	132	0.62	0.74	\$0.0	1	7.56
MWDABU	100	2.26	1.76	0.016	0.022	132	0.62	0.74	\$0.0	1	7.46
MWDABU	100	2.26	1.78	0.016	0.023	133	0.62	0.74	\$0.0	1	7.34
MWDABU	100	2.26	1.76	0.016	0.023	133	0.62	0.74	\$0.0	1	7.22
MWDABU	100	2.26	1.61	0.013	0.023	133	0.62	0.74	\$0.0	1	7.22
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	7.10
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	7.06
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98
MWDABU	100	2.26	1.61	0.016	0.023	133	0.62	0.74	\$0.0	1	6.98</

Study ID	Water		TOC		UV-254		Alkalinity		Turbidity		pH		Coagulant ID	Coagulation Conditions			
	% CRW	% SPW	(mg/L)		(1/cm)		(mg/L as CaCO3)		(NTU)		(I)			Dose	Acid adjusted? (Y/N) blank=N	Base adjusted? (Y/N) blank=N	Coag. pH (I)
			Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.					
MWDJAR11	90		2.67	1.66	0.053	0.026	128		0.49	0.85	8.33		1	80			6.72
MWDJAR11	90		2.67	1.67	0.053	0.022	128		0.49	1.10	8.31		1	90			6.62
MWDJAR12	90		2.95	3.00	0.042	0.043	120		0.67	0.30	8.23		1	0			8.20
MWDJAR12	90		2.95	2.76	0.042	0.032	120		0.67	0.28	8.23		1	10			7.80
MWDJAR12	90		2.95	2.63	0.042	0.032	120		0.67	0.23	8.23		1	20			7.66
MWDJAR12	90		2.95	2.50	0.042	0.031	120		0.67	0.21	8.23		1	30			7.44
MWDJAR12	90		2.95	2.35	0.042	0.029	120		0.67	0.23	8.23		1	40			7.26
MWDJAR12	90		2.95	2.33	0.042	0.029	120		0.67	0.21	8.23		1	50			7.23
MWDJAR12	90		2.95	2.12	0.042	0.032	120		0.67	0.24	8.23		1	60			7.16
MWDJAR12	90		2.95	2.01	0.042	0.029	120		0.67	0.20	8.23		1	70			7.08
MWDJAR12	90		2.95	1.95	0.042	0.029	120		0.67	0.25	8.23		1	80			7.01
MWDJAR12	90		2.95	1.90	0.042	0.027	120		0.67	0.23	8.23		1	90			6.88
MWDJAR12	90		2.95	1.86	0.042	0.028	120		0.67	0.29	8.23		1	100			6.82
MWDJAR12	90		2.95	1.82	0.042	0.027	120		0.67	0.27	8.23		1	110			6.79
MWDJAR12	90		2.95	1.74	0.042	0.028	120		0.67	0.47	8.23		1	120			6.76
MWDJAR12	90		2.95	1.70	0.042	0.028	120		0.67	0.56	8.23		1	130			6.67
MWDJAR12	90		2.95	1.71	0.042	0.026	120		0.67	0.52	8.23		1	140			6.61
MWDJAR12	90		2.95	1.62	0.042	0.026	120		0.67	0.45	8.23		1	150			6.47
MWDJAR12	90		2.95	1.61	0.042	0.027	120		0.67	0.49	8.23		1	160			6.40
MWDJAR12	90		2.95	1.54	0.042	0.027	120		0.67	0.55	8.23		1	170			6.37
MWDJAR12	90		2.95	1.62	0.042	0.028	120		0.67	1.30	8.23		1	180			6.23
MWDJAR12	90		2.95	1.57	0.042	0.026	120		0.67	1.30	8.23		1	190			6.18
MWDJAR12	90		2.95	1.69	0.042	0.052	120		0.67	3.80	8.23		1	200			6.12
MWDJAR13	90		2.25	2.26	0.034	0.035	126		0.77	0.77	8.30		1	0			8.28
MWDJAR13	90		2.25	2.08	0.034	0.023	126		0.77	0.48	8.36		1	10			7.90
MWDJAR13	90		2.25	1.86	0.034	0.021	126		0.77	0.40	8.30		1	20			7.72
MWDJAR13	90		2.25	2.00	0.034	0.019	126		0.77	0.38	8.30		1	30			7.56
MWDJAR13	90		2.25	1.92	0.034	0.018	126		0.77	0.46	8.30		1	40			7.43
MWDJAR13	90		2.25	1.86	0.034	0.018	126		0.77	0.45	8.30		1	50			7.33
MWDJAR13	90		2.25	1.80	0.034	0.018	126		0.77	0.58	8.30		1	60			7.20
MWDJAR13	90		2.25	1.76	0.034	0.015	126		0.77	0.57	8.30		1	70			7.14
MWDJAR13	90		2.25	1.66	0.034	0.013	126		0.77	0.58	8.30		1	80			7.06
MWDJAR13	90		2.25	1.62	0.034	0.013	126		0.77	0.55	8.30		1	90			6.98
MWDJAR13	90		2.25	1.52	0.034	0.012	126		0.77	0.67	8.30		1	100			6.94
MWDJAR13	90		2.25	1.51	0.034	0.012	126		0.77	0.78	8.30		1	110			6.88
MWDJAR14	90		2.31	2.48	0.033	0.033	127		0.58	0.54	8.20		1	0			8.22
MWDJAR14	90		2.31	2.45	0.033	0.025	127		0.58	0.55	8.20		1	10			7.95
MWDJAR14	90		2.31	2.38	0.033	0.023	127		0.58	0.44	8.20		1	20			7.71
MWDJAR14	90		2.31	2.21	0.033	0.021	127		0.58	0.48	8.20		1	30			7.52
MWDJAR14	90		2.31	2.09	0.033	0.020	127		0.58	0.67	8.20		1	40			7.40
MWDJAR14	90		2.31	1.98	0.033	0.018	127		0.58	0.39	8.20		1	50			7.31
MWDJAR14	90		2.31	1.77	0.033	0.017	127		0.58	0.68	8.20		1	60			7.27
MWDJAR14	90		2.31	1.74	0.033	0.015	127		0.58	0.77	8.20		1	70			7.13
MWDJAR14	90		2.31	1.67	0.033	0.017	127		0.58	0.82	8.20		1	80			7.06
MWDJAR14	90		2.31	1.60	0.033	0.015	127		0.58	0.70	8.20		1	90			6.93
MWDJAR14	90		2.31	1.55	0.033	0.015	127		0.58	0.95	8.20		1	100			6.84
MWDJAR14	90		2.31	1.52	0.033	0.014	127		0.58	1.00	8.20		1	110			6.77
MWDJAR14	90		2.31	1.49	0.033	0.012	127		0.58	1.00	8.20		1	120			6.60
MWDJAR14	90		2.31	1.46	0.033	0.016	127		0.58	1.00	8.20		1	130			6.53
MWDJAR14	90		2.31	1.48	0.033		127		0.58		8.20		1	140			
MWDJAR14	90		2.31	1.42	0.033		127		0.58		8.20		1	150			
MWDJAR14	90		2.31	1.35	0.033		127		0.58		8.20		1	160			
MWDJAR15	90		3.17	2.51	0.036	0.041	127		0.47	0.35	8.29		1	0			8.30
MWDJAR15	90		3.17	2.37	0.036	0.034	127		0.47	0.54	8.29		1	10			7.96
MWDJAR15	90		3.17	2.24	0.036	0.031	127		0.47	0.39	8.29		1	20			7.74
MWDJAR15	90		3.17	2.06	0.036	0.028	127		0.47	0.27	8.29		1	30			7.52
MWDJAR15	90		3.17	2.01	0.036	0.026	127		0.47	0.59	8.29		1	40			7.39
MWDJAR15	90		3.17	1.86	0.036	0.028	127		0.47	0.56	8.29		1	50			7.32
MWDJAR15	90		3.17	1.76	0.036	0.025	127		0.47	0.58	8.29		1	60			7.23
MWDJAR15	90		3.17	1.72	0.036	0.024	127		0.47	0.65	8.29		1	70			7.15
MWDJAR15	90		3.17	1.66	0.036	0.024	127		0.47	0.77	8.29		1	80			7.06
MWDJAR15	90		3.17	1.54	0.036	0.024	127		0.47	0.63	8.29		1	90			7.03
MWDJAR15	90		3.17	1.58	0.036	0.022	127		0.47	0.78	8.29		1	100			6.93
MWDJAR16	90		2.43	2.52	0.041	0.042	117		0.42	0.32	8.25		1	0			8.28
MWDJAR16	90		2.43	2.50	0.041	0.031	117		0.42	0.35	8.25		1	10			8.01
MWDJAR16	90		2.43	2.32	0.041	0.026	117		0.42	0.28	8.25		1	20			7.80
MWDJAR16	90		2.43	2.19	0.041	0.025	117		0.42	0.24	8.25		1	30			7.68
MWDJAR16	90		2.43	2.05	0.041	0.024	117		0.42	0.27	8.25		1	40			7.55
MWDJAR16	90		2.43	2.06	0.041	0.024	117		0.42	0.30	8.25		1	50			7.44
MWDJAR16	90		2.43	1.99	0.041	0.022	117		0.42	0.30	8.25		1	60			7.36
MWDJAR16	90		2.43	1.92	0.041	0.021	117		0.42	0.35	8.25		1	70			7.27
MWDJAR16	90		2.43	1.87	0.041	0.021	117		0.42	0.33	8.25		1	80			7.16
MWDJAR16	90		2.43	1.82	0.041	0.021	117		0.42	0.36	8.25		1	90			7.07
MWDJAR16	90		2.43	1.85	0.041	0.021	117		0.42	0.36	8.25		1	100			7.00
MWDJAR16	90		2.43	1.75	0.041	0.020	117		0.42	0.39	8.25		1	110			6.84
MWDJAR16	90		2.43	1.73	0.041	0.019	117		0.42	0.46	8.25		1	120			6.77
MWDJAR1																	

Study ID	Water		TOC		UV-254		Alkalinity		Turbidity		pH		Coagulation Conditions				
	% CRW	% SPW	(mg/L)		(1/cm)		(mg/L as CaCO3)		(NTU)		()		Coagulant ID	Dose	Acid adjusted? (Y/N)	Base adjusted? (Y/N)	Coag. pH ()
			Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.					
MWDJAR17	80		2.55	2.02	0.061	0.034	114		1.20	0.44	8.09		1	40			6.93
MWDJAR17	80		2.55	1.96	0.061	0.042	114		1.20	1.10	8.09		1	70			6.60
MWDJAR17	80		2.55	1.84	0.061	0.032	114		1.20	0.95	8.09		1	80			6.51
MWDJAR17	80		2.55	1.74	0.061	0.031	114		1.20	0.85	8.09		1	90			6.43
MWDJAR17	80		2.55	1.64	0.061	0.033	114		1.20	1.40	8.09		1	100			6.27
MWDJAR17	80		2.55	1.67	0.061	0.033	114		1.20	1.30	8.09		1	110			6.17
MWDJAR17	80		2.55	1.62	0.061	0.033	114		1.20	1.30	8.09		1	120			6.14
MWDJAR18	80		2.45	2.59	0.054	0.061	121		0.78	0.68	8.22		1	0			8.23
MWDJAR18	80		2.45	2.66	0.054	0.045	121		0.78	0.66	8.22		1	10			7.85
MWDJAR18	80		2.45	2.54	0.054	0.039	121		0.78	0.60	8.22		1	20			7.61
MWDJAR18	80		2.45	2.32	0.054	0.036	121		0.78	0.65	8.22		1	30			7.45
MWDJAR18	80		2.45	2.35	0.054	0.041	121		0.78	0.54	8.22		1	40			7.35
MWDJAR18	80		2.45	2.22	0.054	0.032	121		0.78	0.67	8.22		1	50			7.23
MWDJAR18	80		2.45	1.95	0.054	0.034	121		0.78	0.82	8.22		1	60			6.97
MWDJAR18	80		2.45	1.97	0.054	0.032	121		0.78	0.76	8.22		1	70			7.00
MWDJAR18	80		2.45	1.77	0.054	0.031	121		0.78	0.78	8.22		1	80			6.90
MWDJAR18	80		2.45	1.82	0.054	0.034	121		0.78	0.75	8.22		1	90			6.88
MWDJAR18	80		2.45	1.76	0.054	0.035	121		0.78	0.73	8.22		1	100			6.82
MWDJAR18	80		2.45	1.75	0.054	0.037	121		0.78	1.00	8.22		1	110			6.77
MWDJAR19	80		2.70	2.87	0.049	0.048	122		0.57	0.55	8.38		1	0			8.46
MWDJAR19	80		2.70	2.65	0.049	0.031	122		0.57	0.69	8.38		1	10			7.85
MWDJAR19	80		2.70	2.44	0.049	0.027	122		0.57	0.60	8.38		1	20			7.64
MWDJAR19	80		2.70	2.22	0.049	0.025	122		0.57	0.56	8.38		1	30			7.32
MWDJAR19	80		2.70	2.04	0.049	0.023	122		0.57	0.59	8.38		1	40			7.18
MWDJAR19	80		2.70	2.02	0.049	0.021	122		0.57	0.79	8.38		1	50			7.13
MWDJAR19	80		2.70	1.97	0.049	0.021	122		0.57	0.75	8.38		1	60			6.80
MWDJAR19	80		2.70	1.85	0.049	0.018	122		0.57	0.81	8.38		1	70			6.79
MWDJAR19	80		2.70	1.78	0.049	0.018	122		0.57	0.97	8.38		1	80			6.71
MWDJAR19	80		2.70	1.88	0.049	0.015	122		0.57	0.89	8.38		1	90			6.67
MWDJAR19	80		2.70	1.77	0.049	0.015	122		0.57	0.84	8.38		1	100			6.56
MWDJAR19	80		2.70	1.88	0.049	0.016	122		0.57	1.50	8.38		1	110			6.52
MWDJAR2	100		2.53	2.90	0.042	0.045	133		0.85	0.90	8.38		1	0			8.45
MWDJAR2	100		2.53	2.80	0.042	0.036	133		0.85	0.71	8.38		1	10			8.02
MWDJAR2	100		2.53	2.68	0.042	0.030	133		0.85	0.53	8.38		1	20			7.72
MWDJAR2	100		2.53	2.51	0.042	0.027	133		0.85	0.40	8.38		1	30			7.46
MWDJAR2	100		2.53	2.19	0.042	0.029	133		0.85	0.64	8.38		1	40			7.34
MWDJAR2	100		2.53	2.30	0.042	0.028	133		0.85	0.57	8.38		1	50			7.26
MWDJAR2	100		2.53	2.03	0.042	0.017	133		0.85	0.78	8.38		1	60			6.96
MWDJAR2	100		2.53	1.99	0.042	0.018	133		0.85	1.10	8.38		1	70			6.85
MWDJAR2	100		2.53	1.90	0.042	0.018	133		0.85	1.20	8.38		1	80			6.84
MWDJAR2	100		2.53	1.90	0.042	0.020	133		0.85	1.30	8.38		1	90			6.81
MWDJAR20	80		2.79	2.87	0.053	0.055	114		0.54	0.38	8.21		1	0			8.15
MWDJAR20	80		2.79	2.46	0.053	0.040	114		0.54	0.37	8.21		1	10			7.45
MWDJAR20	80		2.79	2.60	0.053	0.044	114		0.54	0.24	8.21		1	20			7.58
MWDJAR20	80		2.79	2.39	0.053	0.038	114		0.54	0.24	8.21		1	30			7.42
MWDJAR20	80		2.79	2.28	0.053	0.035	114		0.54	0.24	8.21		1	40			7.30
MWDJAR20	80		2.79	2.20	0.053	0.036	114		0.54	0.20	8.21		1	50			7.21
MWDJAR20	80		2.79	2.13	0.053	0.036	114		0.54	0.20	8.21		1	60			7.19
MWDJAR20	80		2.79	2.09	0.053	0.032	114		0.54	0.23	8.21		1	70			7.10
MWDJAR20	80		2.79	1.97	0.053	0.034	114		0.54	0.26	8.21		1	80			7.01
MWDJAR20	80		2.79	1.95	0.053	0.033	114		0.54	0.27	8.21		1	90			6.97
MWDJAR20	80		2.79	1.83	0.053	0.032	114		0.54	0.27	8.21		1	100			6.82
MWDJAR20	80		2.79	1.79	0.053	0.031	114		0.54	0.63	8.21		1	110			6.80
MWDJAR20	80		2.79	1.74	0.053	0.031	114		0.54	0.39	8.21		1	120			6.74
MWDJAR20	80		2.79	1.70	0.053	0.027	114		0.54	0.43	8.21		1	130			6.62
MWDJAR20	80		2.79	1.62	0.053	0.032	114		0.54	0.53	8.21		1	140			6.48
MWDJAR20	80		2.79	1.61	0.053	0.030	114		0.54	0.58	8.21		1	150			6.53
MWDJAR20	80		2.79	1.61	0.053	0.030	114		0.54	0.53	8.21		1	160			6.42
MWDJAR20	80		2.79	1.63	0.053	0.048	114		0.54	0.66	8.21		1	170			6.35
MWDJAR20	80		2.79	1.47	0.053	0.032	114		0.54	1.20	8.21		1	180			6.19
MWDJAR20	80		2.79	1.55	0.053	0.032	114		0.54	1.40	8.21		1	190			6.10
MWDJAR20	80		2.79	1.52	0.053	0.027	114		0.54	1.50	8.21		1	200			6.08
MWDJAR21	80		2.43	2.42	0.036	0.038	121		0.83	0.73	8.22		1	0			8.23
MWDJAR21	80		2.43	2.42	0.036	0.028	121		0.83	0.69	8.22		1	10			7.84
MWDJAR21	80		2.43	2.29	0.036	0.025	121		0.83	0.52	8.22		1	20			7.60
MWDJAR21	80		2.43	2.09	0.036	0.023	121		0.83	0.32	8.22		1	30			7.47
MWDJAR21	80		2.43	2.04	0.036	0.021	121		0.83	0.46	8.22		1	40			7.35
MWDJAR21	80		2.43	1.97	0.036	0.019	121		0.83	0.57	8.22		1	50			7.28
MWDJAR21	80		2.43	1.80	0.036	0.017	121		0.83	0.51	8.22		1	60			7.30
MWDJAR21	80		2.43	1.77	0.036	0.017	121		0.83	0.57	8.22		1	70			7.28
MWDJAR21	80		2.43	1.73	0.036	0.015	121		0.83	0.67	8.22		1	80			7.13
MWDJAR21	80		2.43	1.72	0.036	0.014	121		0.83	0.71	8.22		1	90			7.06
MWDJAR21	80		2.43	1.70	0.036	0.014	121		0.83	0.72	8.22		1	100			6.96
MWDJAR21	80		2.43	1.69	0.036	0.013	121		0.83	0.98	8.22		1	110			6.95
MWDJAR21	80		2.43	2.53	0.038	0.038	121		0.78	0.71	8.15		1	0			8.25
MWDJAR21	80		2.43	2.31	0.038	0.029	121		0.78	0.50	8.15						

Study ID	Water		TOC		UV-254		Alkalinity		Turbidity		pH		Coagulation Conditions				
	% CRW	% SPW	(mg/L)		(1/cm)		(mg/L as CaCO3)		(NTU)		()		Coagulant ID	Dose	Acid adjusted? (Y/N)	Base adjusted? (Y/N)	Coag. pH ()
			Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.					
MWDJAR23	80		2.51	2.10	0.050	0.028	121		0.43	0.36	8.32		1	40			7.39
MWDJAR23	80		2.51	1.92	0.050	0.024	121		0.43	0.40	8.32		1	50			7.28
MWDJAR23	80		2.51	1.79	0.050	0.023	121		0.43	0.42	8.32		1	60			7.21
MWDJAR23	80		2.51	1.75	0.050	0.018	121		0.43	0.45	8.32		1	70			7.16
MWDJAR23	80		2.51	1.62	0.050	0.022	121		0.43	0.48	8.32		1	80			7.07
MWDJAR23	80		2.51	1.56	0.050	0.019	121		0.43	0.55	8.32		1	90			7.00
MWDJAR23	80		2.51	1.56	0.050	0.022	121		0.43	0.58	8.32		1	100			6.95
MWDJAR24	80		2.57	2.45	0.045	0.046	113		0.65	0.59	8.11		1	0			8.20
MWDJAR24	80		2.57	2.49	0.045	0.035	113		0.65	0.32	8.11		1	10			7.95
MWDJAR24	80		2.57	2.32	0.045	0.031	113		0.65	0.29	8.11		1	20			7.80
MWDJAR24	80		2.57	2.09	0.045	0.027	113		0.65	0.28	8.11		1	30			7.62
MWDJAR24	80		2.57	2.05	0.045	0.027	113		0.65	0.28	8.11		1	40			7.50
MWDJAR24	80		2.57	1.90	0.045	0.026	113		0.65	0.27	8.11		1	50			7.39
MWDJAR24	80		2.57	1.90	0.045	0.025	113		0.65	0.27	8.11		1	60			7.19
MWDJAR24	80		2.57	2.03	0.045	0.023	113		0.65	0.27	8.11		1	70			7.11
MWDJAR24	80		2.57	1.92	0.045	0.021	113		0.65	0.28	8.11		1	80			7.03
MWDJAR24	80		2.57	1.80	0.045	0.021	113		0.65	0.40	8.11		1	90			6.93
MWDJAR24	80		2.57	1.69	0.045	0.021	113		0.65	0.44	8.11		1	100			6.90
MWDJAR24	80		2.57	1.61	0.045	0.020	113		0.65	0.45	8.11		1	110			6.86
MWDJAR24	80		2.57	1.61	0.045	0.020	113		0.65	0.54	8.11		1	120			6.78
MWDJAR24	80		2.57	1.64	0.045	0.020	113		0.65	0.62	8.11		1	130			6.67
MWDJAR24	80		2.57	1.53	0.045	0.019	113		0.65	0.80	8.11		1	140			6.58
MWDJAR24	80		2.57	1.69	0.045	0.018	113		0.65	1.20	8.11		1	150			6.53
MWDJAR24	80		2.57	1.57	0.045	0.018	113		0.65	1.20	8.11		1	160			6.45
MWDJAR24	80		2.57	1.44	0.045	0.017	113		0.65	0.89	8.11		1	170			6.37
MWDJAR24	80		2.57	1.46	0.045	0.017	113		0.65	1.53	8.11		1	180			6.30
MWDJAR24	80		2.57	1.36	0.045	0.016	113		0.65	0.76	8.11		1	190			6.22
MWDJAR24	80		2.57	1.35	0.045	0.015	113		0.65	0.77	8.11		1	200			6.13
MWDJAR24	80		2.57	1.40	0.045	0.015	113		0.65	0.75	8.11		1	210			6.04
MWDJAR24	80		2.57	1.29	0.045	0.015	113		0.65	0.95	8.11		1	220			5.91
MWDJAR25	70		2.67	2.67	0.065		109		0.84	0.75	7.84		1	0			7.92
MWDJAR25	70		2.67	2.59	0.065	0.054	109		0.84	0.62	7.84		1	10			7.64
MWDJAR25	70		2.67	2.49	0.065	0.049	109		0.84	0.65	7.84		1	20			7.41
MWDJAR25	70		2.67	2.20	0.065	0.039	109		0.84	0.43	7.84		1	30			7.13
MWDJAR25	70		2.67	2.10	0.065	0.037	109		0.84	0.50	7.84		1	40			6.98
MWDJAR25	70		2.67	1.97	0.065	0.037	109		0.84	0.76	7.84		1	50			6.85
MWDJAR25	70		2.67	1.92	0.065	0.035	109		0.84	0.77	7.84		1	60			6.72
MWDJAR25	70		2.67	1.82	0.065	0.028	109		0.84	0.90	7.84		1	70			6.58
MWDJAR25	70		2.67	1.82	0.065	0.026	109		0.84	0.85	7.84		1	80			6.50
MWDJAR25	70		2.67	1.66	0.065	0.026	109		0.84	0.87	7.84		1	90			6.42
MWDJAR25	70		2.67	1.68	0.065	0.024	109		0.84	0.95	7.84		1	100			6.22
MWDJAR26	70		2.50	2.56	0.055	0.058	115		0.68	0.82	8.22		1	0			8.22
MWDJAR26	70		2.50	2.53	0.055	0.046	115		0.68	0.76	8.22		1	10			7.79
MWDJAR26	70		2.50	2.39	0.055	0.041	115		0.68	0.78	8.22		1	20			7.57
MWDJAR26	70		2.50	2.29	0.055	0.038	115		0.68	0.75	8.22		1	30			7.43
MWDJAR26	70		2.50	2.01	0.055	0.035	115		0.68	0.73	8.22		1	40			7.28
MWDJAR26	70		2.50	2.02	0.055	0.035	115		0.68	1.00	8.22		1	50			7.18
MWDJAR26	70		2.50	1.96	0.055	0.033	115		0.68	0.67	8.22		1	60			6.97
MWDJAR26	70		2.50	1.75	0.055	0.034	115		0.68	0.70	8.22		1	70			7.00
MWDJAR26	70		2.50	1.75	0.055	0.036	115		0.68	0.70	8.22		1	80			6.81
MWDJAR26	70		2.50	1.71	0.055	0.031	115		0.68	0.41	8.22		1	90			6.78
MWDJAR26	70		2.50	1.62	0.055	0.034	115		0.68	0.57	8.22		1	100			6.77
MWDJAR26	70		2.50	1.72	0.055	0.031	115		0.68	0.72	8.22		1	110			6.56
MWDJAR26	70		2.50	1.63	0.055	0.032	115		0.68	1.20	8.22		1	120			6.46
MWDJAR26	70		2.50	1.56	0.055	0.033	115		0.68	1.40	8.22		1	130			6.39
MWDJAR26	70		2.50	1.57	0.055	0.035	115		0.68	1.70	8.22		1	140			6.33
MWDJAR27	70		3.14	2.94	0.064	0.061	115		0.69	0.62	8.32		1	0			8.29
MWDJAR27	70		3.14	2.38	0.064	0.027	115		0.69	0.48	8.32		1	10			7.24
MWDJAR27	70		3.14	2.62	0.064	0.030	115		0.69	0.43	8.32		1	20			7.33
MWDJAR27	70		3.14	2.48	0.064	0.025	115		0.69	0.41	8.32		1	30			7.25
MWDJAR27	70		3.14	2.44	0.064	0.027	115		0.69	0.52	8.32		1	40			7.05
MWDJAR27	70		3.14	2.14	0.064	0.024	115		0.69	0.55	8.32		1	50			6.99
MWDJAR27	70		3.14	3.87	0.064	0.029	115		0.69	0.61	8.32		1	60			6.78
MWDJAR27	70		3.14	2.81	0.064	0.020	115		0.69	0.71	8.32		1	70			6.67
MWDJAR27	70		3.14	1.93	0.064	0.020	115		0.69	0.62	8.32		1	80			6.63
MWDJAR27	70		3.14	1.83	0.064	0.018	115		0.69	0.74	8.32		1	90			6.50
MWDJAR27	70		3.14	1.72	0.064	0.029	115		0.69	0.84	8.32		1	100			6.42
MWDJAR27	70		3.14	1.96	0.064		115		0.69	1.00	8.32		1	110			6.33
MWDJAR27	70		3.14	1.72	0.064	0.025	115		0.69	1.70	8.32		1	120			6.19
MWDJAR27	70		3.14	1.92	0.064	0.019	115		0.69	2.10	8.32		1	130			6.15
MWDJAR27	70		3.14	1.76	0.064	0.017	115		0.69	1.70	8.32		1	140			6.05
MWDJAR27	70		3.14	1.75	0.064	0.016	115		0.69	3.10	8.32		1	150			5.85
MWDJAR28	70		2.74	2.82	0.058	0.057	111		0.47	0.57	8.12		1	0			8.17
MWDJAR28	70		2.74	2.63	0.058	0.047	111		0.47	0.22	8.12		1	10			7.91
MWDJAR28	70		2.74	2.45	0.058	0.042	111		0.47	0.20	8.12		1	20			7.80
MWDJAR28	70		2.74	2.39	0.058	0.039	111		0.47	0.17	8.12		1	30			

Study ID	Water	TOC		UV-254		Absorbance		Turbidity		pH		Concitant	Concentration		Dose	Acid		Base		CASP
		% CRV	% SPW	(mg/L)	(f/cm)	(mg/L as CaCO3)	(NTU)	(f)	(f)	(f)	(f)		(see above)	(f)		adjusted?	(f)	adjusted?	(f)	
				Raw	Fit.	Raw	Fit.	Raw	Fit.	Raw	Fit.						Blank	Blank		
AMDIAB27	70			2.50	2.55	0.040	0.040	115		0.68	0.68	8.20								8.20
AMDIAB27	70			2.50	2.44	0.040	0.040	115		0.68	0.57	8.20								7.92
AMDIAB27	70			2.50	2.25	0.040	0.026	115		0.68	0.55	8.20								7.69
AMDIAB27	70			2.50	2.12	0.040	0.020	115		0.68	0.44	8.20								7.51
AMDIAB27	70			2.50	1.91	0.040	0.020	115		0.68	0.54	8.20								7.48
AMDIAB27	70			2.50	1.80	0.040	0.020	115		0.68	0.72	8.20								7.39
AMDIAB27	70			2.50	1.76	0.040	0.018	115		0.68	0.77	8.20								7.06
AMDIAB27	70			2.50	1.76	0.040	0.018	115		0.68	0.86	8.20								6.99
AMDIAB27	70			2.50	1.76	0.040	0.017	115		0.68	0.61	8.20								6.93
AMDIAB27	70			2.50	1.65	0.040	0.016	115		0.68	0.50	8.20								6.90
AMDIAB27	70			2.50	1.60	0.040	0.015	115		0.68	0.50	8.20								6.87
AMDIAB27	70			2.50	1.49	0.040	0.015	115		0.68	0.78	8.20								6.77
AMDIAB27	70			2.50	1.47	0.040	0.017	115		0.68	1.10	8.20								6.74
AMDIAB27	70			2.50	1.47	0.040	0.016	115		0.68	1.10	8.20								6.63
AMDIAB27	70			2.50	1.41	0.040	0.014	115		0.68	1.10	8.20								6.58
AMDIAB27	70			2.50	1.39	0.040	0.014	115		0.68	1.20	8.20								6.53
AMDIAB27	70			2.50	1.37	0.040	0.014	115		0.68	1.20	8.20								6.37
AMDIAB27	70			2.50	1.25	0.040	0.037	134		0.42	0.35	8.41								8.40
AMDIAB27	70			2.50	1.20	0.040	0.039	134		0.42	0.49	8.41								7.84
AMDIAB27	70			2.50	1.10	0.040	0.029	134		0.42	0.49	8.41								7.65
AMDIAB27	70			2.50	1.00	0.040	0.025	134		0.42	0.41	8.41								7.59
AMDIAB27	70			2.50	0.94	0.040	0.023	134		0.42	0.60	8.41								7.33
AMDIAB27	70			2.50	0.85	0.040	0.022	134		0.42	0.61	8.41								7.13
AMDIAB27	70			2.50	0.78	0.040	0.022	134		0.42	0.78	8.41								6.93
AMDIAB27	70			2.50	0.65	0.040	0.019	134		0.42	0.36	8.41								6.93
AMDIAB27	70			2.50	0.60	0.040	0.020	134		0.42	1.10	8.41								6.80
AMDIAB27	70			2.50	0.51	0.042	0.047	116		0.42	0.58	8.14								8.12
AMDIAB27	70			2.44	2.50	0.042	0.032	116		0.42	0.61	8.14								7.81
AMDIAB27	70			2.44	2.20	0.042	0.024	116		0.42	0.50	8.14								7.55
AMDIAB27	70			2.44	2.04	0.042	0.024	116		0.42	0.50	8.14								7.38
AMDIAB27	70			2.44	1.96	0.042	0.022	116		0.42	0.70	8.14								7.29
AMDIAB27	70			2.44	1.83	0.042	0.021	116		0.42	0.55	8.14								7.23
AMDIAB27	70			2.44	1.92	0.042	0.019	116		0.42	0.58	8.14								7.00
AMDIAB27	70			2.44	1.86	0.042	0.019	116		0.42	0.64	8.14								6.88
AMDIAB27	70			2.44	1.88	0.042	0.017	116		0.42	0.72	8.14								6.82
AMDIAB27	70			2.44	1.84	0.042	0.016	116		0.42	0.54	8.14								6.79
AMDIAB27	70			2.44	1.83	0.042	0.015	116		0.42	1.10	8.14								6.74
AMDIAB27	70			2.44	1.79	0.042	0.015	116		0.42	0.85	8.14								6.70
AMDIAB27	70			2.44	1.67	0.042	0.019	116		0.42	0.75	8.14								6.61
AMDIAB27	70			2.44	1.56	0.042	0.018	116		0.42	1.10	8.14								6.43
AMDIAB27	70			2.44	1.54	0.042	0.017	116		0.42	0.87	8.14								6.36
AMDIAB27	70			2.44	1.42	0.042	0.016	116		0.42	1.20	8.14								6.31
AMDIAB27	70			2.44	1.15	0.042	0.012	116		0.42	1.20	8.14								6.27
AMDIAB27	70			2.40	2.46	0.055	0.055	114		0.45	0.40	8.29								8.30
AMDIAB27	70			2.40	2.22	0.055	0.036	114		0.45	0.55	8.29								7.91
AMDIAB27	70			2.40	2.25	0.055	0.036	114		0.45	0.50	8.29								7.64
AMDIAB27	70			2.40	2.10	0.055	0.031	114		0.45	0.55	8.29								7.53
AMDIAB27	70			2.40	2.00	0.055	0.031	114		0.45	0.53	8.29								7.32
AMDIAB27	70			2.40	1.94	0.055	0.029	114		0.45	0.51	8.29								7.27
AMDIAB27	70			2.40	1.87	0.055	0.028	114		0.45	0.42	8.29								7.20
AMDIAB27	70			2.40	1.81	0.055	0.026	114		0.45	0.48	8.29								7.08
AMDIAB27	70			2.40	1.72	0.055	0.024	114		0.45	0.48	8.29								7.00
AMDIAB27	70			2.40	1.62	0.055	0.023	114		0.45	0.48	8.29								6.96
AMDIAB27	70			2.40	1.62	0.055	0.023	114		0.45	0.57	8.29								6.86
AMDIAB27	70			2.40	1.58	0.055	0.021	114		0.45	0.50	8.29								6.72
AMDIAB27	70			2.40	1.52	0.055	0.021	114		0.45	0.67	8.29								6.68
AMDIAB27	70			2.40	1.47	0.055	0.020	114		0.45	0.63	8.29								6.59
AMDIAB27	70			2.40	1.40	0.055	0.020	114		0.45	0.75	8.29								6.52
AMDIAB27	70			2.40	1.40	0.055	0.019	114		0.45	0.77	8.29								6.46
AMDIAB27	70			2.40	1.46	0.055	0.018	114		0.45	0.71	8.29								6.39
AMDIAB27	70			2.40	1.36	0.055	0.018	114		0.45	1.10	8.29								6.35
AMDIAB27	70			2.40	1.30	0.055	0.017	114		0.45	1.10	8.29								6.23
AMDIAB27	70			2.40	1.17	0.055	0.016	114		0.45	1.10	8.29								6.34
AMDIAB27	70			2.40	1.12	0.055	0.016	114		0.45	1.40	8.29								6.23
AMDIAB27	70			2.40	2.51	0.048	0.047	106		0.52	0.44	8.06								8.07
AMDIAB27	70			2.40	2.36	0.048	0.047	106		0.52	0.37	8.06								7.90
AMDIAB27	70			2.40	2.18	0.048	0.040	106		0.52	0.36	8.06								7.83
AMDIAB27	70			2.40	2.18	0.048	0.040	106		0.52	0.36	8.06								7.51
AMDIAB27	70			2.40	1.96	0.048	0.032	106		0.52	0.32	8.06								7.41
AMDIAB27	70			2.40	2.07	0.048	0.032	106		0.52	0.59	8.06								7.41
AMDIAB27	70			2.40	2.04	0.048	0.030	106		0.52	0.59	8.06								7.27
AMDIAB27	70			2.40	1.81	0.048	0.027	106		0.52	0.50	8.06								7.27
AMDIAB27	70			2.40	1.80	0.048	0.022	106		0.52	0.50	8.06								7.14
AMDIAB27	70			2.40	1.74	0.048	0.022	106		0.52	0.53	8.06								7.04
AMDIAB27	70			2.40	1.72	0.048	0.022	106		0.52	0.30	8.06								6.97
AMDIAB27	70			2.40	1.67	0.048	0.023	106		0.52	0.27	8.06								6.86
AMDIAB27	70			2.40	1.67	0.048	0.023	106		0.52	0.42	8.06								6.83
AMDIAB27	70			2.40	1.60	0.048	0.021	106		0.52	0.39	8.06								6.80
AMDIAB27	70			2.40	1.59	0.048	0.019	106		0.52	0.49	8.06								6.73
AMDIAB27	70			2.40	1.62	0.048	0.018	106		0.52	0.53	8.06								6.66
AMDIAB27	70			2.40	1.53	0.048	0.018	106		0.52	0.56	8.06								6.55
AMDIAB27	70			2.40	1.55	0.048	0.018	106		0.52	0.									

Study ID	Water	TOC (mg/L)	UV ₂₅₄ (1/cm)	Alkalinity (mg/L as CaCO ₃)	Turbidity (NTU)	pH	Coagulation Conditions									
							Coagulant	Dose	Adjusted pH	Coag pH						
	% CRN	% SPV	Raw	Fill	Raw	Fill	Raw	Fill	Raw	Fill						
							(set above)		drinking	drinking						
MWDIARJ1	60		2.72	2.15	0.074	0.041	104		1.70	0.75	8.03	1	40		6.92	
MWDIARJ1	60		2.72	2.09	0.074	0.042	104		1.70	0.74	8.03	1	50		6.92	
MWDIARJ1	60		2.72	2.04	0.074	0.041	104		1.70	0.66	8.03	1	60		6.77	
MWDIARJ1	60		2.72	1.92	0.074	0.038	104		1.70	0.31	8.03	1	70		6.49	
MWDIARJ1	60		2.72	1.86	0.074	0.038	104		1.70	1.10	8.03	1	80		6.43	
MWDIARJ1	60		2.72	1.75	0.074	0.035	104		1.70	0.97	8.03	1	90		6.26	
MWDIARJ1	60		2.72	1.67	0.074	0.037	104		1.70	2.00	8.03	1	100		6.11	
MWDIARJ1	60		2.51	2.07	0.064	0.043	109		0.77	0.67	8.27	1	0		8.27	
MWDIARJ1	60		2.51	2.07	0.064	0.043	109		0.77	0.70	8.27	1	10		7.79	
MWDIARJ1	60		2.51	2.06	0.064	0.041	109		0.77	0.70	8.27	1	20		7.57	
MWDIARJ1	60		2.51	2.04	0.064	0.035	109		0.77	0.61	8.27	1	30		7.43	
MWDIARJ1	60		2.51	2.04	0.064	0.035	109		0.77	0.57	8.27	1	40		7.28	
MWDIARJ1	60		2.51	2.04	0.064	0.035	109		0.77	0.57	8.27	1	50		7.18	
MWDIARJ1	60		2.51	1.91	0.064	0.021	109		0.77	0.57	8.27	1	60		7.09	
MWDIARJ1	60		2.51	1.99	0.064	0.030	109		0.77	0.64	8.27	1	70		6.98	
MWDIARJ1	60		2.51	1.82	0.064	0.019	109		0.77	0.66	8.27	1	80		6.91	
MWDIARJ1	60		2.51	1.76	0.064	0.027	109		0.77	0.73	8.27	1	90		6.81	
MWDIARJ1	60		2.51	1.69	0.064	0.023	109		0.77	0.72	8.27	1	100		6.76	
MWDIARJ1	60		2.51	1.64	0.064	0.032	109		0.77	0.88	8.27	1	110		6.68	
MWDIARJ1	60		2.51	1.48	0.064	0.035	109		0.77	1.40	8.27	1	120		6.45	
MWDIARJ1	60		2.51	1.47	0.064	0.036	109		0.77	1.50	8.27	1	130		6.41	
MWDIARJ1	60		2.44	2.07	0.081	0.077	111		0.74	0.65	8.36	1	0		8.34	
MWDIARJ1	60		2.44	2.07	0.081	0.054	111		0.74	0.58	8.36	1	10		7.86	
MWDIARJ1	60		2.44	2.02	0.081	0.064	111		0.74	0.56	8.36	1	20		7.57	
MWDIARJ1	60		2.44	2.06	0.081	0.038	111		0.74	0.56	8.36	1	30		7.18	
MWDIARJ1	60		2.44	2.09	0.081	0.030	111		0.74	0.47	8.36	1	40		7.12	
MWDIARJ1	60		2.44	2.13	0.081	0.031	111		0.74	0.67	8.36	1	50		7.00	
MWDIARJ1	60		2.44	2.27	0.081	0.043	111		0.74	0.67	8.36	1	60		6.83	
MWDIARJ1	60		2.44	2.15	0.081	0.034	111		0.74	0.72	8.36	1	70		6.78	
MWDIARJ1	60		2.44	2.02	0.081	0.028	111		0.74	0.84	8.36	1	80		6.60	
MWDIARJ1	60		2.44	2.08	0.081	0.028	111		0.74	0.70	8.36	1	90		6.61	
MWDIARJ1	60		2.44	1.88	0.081	0.026	111		0.74	0.58	8.36	1	100		6.54	
MWDIARJ1	60		2.44	1.81	0.081	0.028	111		0.74	0.68	8.36	1	110		6.38	
MWDIARJ1	60		2.44	1.77	0.081	0.028	111		0.74	1.10	8.36	1	120		6.17	
MWDIARJ1	60		2.44	1.64	0.081	0.027	111		0.74	1.10	8.36	1	130		6.06	
MWDIARJ1	60		2.44	1.65	0.081	0.031	111		0.74	1.20	8.36	1	140		6.00	
MWDIARJ1	60		2.44	1.64	0.081	0.028	111		0.74	1.50	8.36	1	150		5.93	
MWDIARJ1	60		2.22	2.08	0.064	0.063	107		0.43	0.60	8.10	1	0		8.13	
MWDIARJ1	60		2.22	2.08	0.064	0.051	107		0.43	0.60	8.10	1	10		7.78	
MWDIARJ1	60		2.22	2.00	0.064	0.047	107		0.43	0.50	8.10	1	20		7.58	
MWDIARJ1	60		2.22	2.09	0.064	0.044	107		0.43	0.57	8.10	1	30		7.43	
MWDIARJ1	60		2.22	2.04	0.064	0.040	107		0.43	0.58	8.10	1	40		7.31	
MWDIARJ1	60		2.22	2.04	0.064	0.038	107		0.43	0.52	8.10	1	50		7.19	
MWDIARJ1	60		2.22	2.04	0.064	0.037	107		0.43	0.50	8.10	1	60		7.46	
MWDIARJ1	60		2.22	2.04	0.064	0.035	107		0.43	0.52	8.10	1	70		7.25	
MWDIARJ1	60		2.22	2.17	0.064	0.034	107		0.43	0.57	8.10	1	80		7.06	
MWDIARJ1	60		2.22	2.02	0.064	0.033	107		0.43	0.56	8.10	1	90		6.95	
MWDIARJ1	60		2.22	2.02	0.064	0.030	107		0.43	0.57	8.10	1	100		6.86	
MWDIARJ1	60		2.22	1.98	0.064	0.026	107		0.43	0.45	8.10	1	110		6.78	
MWDIARJ1	60		2.22	1.74	0.064	0.026	107		0.43	0.56	8.10	1	120		6.77	
MWDIARJ1	60		2.22	1.72	0.064	0.027	107		0.43	0.56	8.10	1	130		6.60	
MWDIARJ1	60		2.22	1.72	0.064	0.026	107		0.43	0.54	8.10	1	140		6.58	
MWDIARJ1	60		2.22	1.81	0.064	0.025	107		0.43	0.55	8.10	1	150		6.49	
MWDIARJ1	60		2.22	1.70	0.064	0.029	107		0.43	0.55	8.10	1	160		6.51	
MWDIARJ1	60		2.22	1.71	0.064	0.027	107		0.43	0.47	8.10	1	170		6.34	
MWDIARJ1	60		2.22	1.64	0.064	0.030	107		0.43	1.15	8.10	1	180		6.21	
MWDIARJ1	60		2.56	2.04	0.039	0.038	109		0.88	0.70	8.15	1	0		8.35	
MWDIARJ1	60		2.56	2.04	0.039	0.038	109		0.88	0.56	8.15	1	10		7.95	
MWDIARJ1	60		2.56	2.35	0.039	0.036	109		0.88	0.52	8.15	1	20		7.78	
MWDIARJ1	60		2.56	2.31	0.039	0.026	104		0.88	0.30	8.15	1	30		7.57	
MWDIARJ1	60		2.56	2.22	0.039	0.024	109		0.88	0.58	8.15	1	40		7.40	
MWDIARJ1	60		2.56	2.07	0.039	0.023	109		0.88	0.54	8.15	1	50		7.29	
MWDIARJ1	60		2.56	1.84	0.039	0.021	109		0.88	0.56	8.15	1	60		7.25	
MWDIARJ1	60		2.56	1.81	0.039	0.019	109		0.88	0.65	8.15	1	70		7.12	
MWDIARJ1	60		2.56	1.76	0.039	0.017	109		0.88	0.65	8.15	1	80		7.01	
MWDIARJ1	60		2.56	1.63	0.039	0.015	109		0.88	0.67	8.15	1	90		6.86	
MWDIARJ1	60		2.56	1.62	0.039	0.016	109		0.88	0.86	8.15	1	100		6.88	
MWDIARJ1	60		2.56	1.58	0.039	0.015	109		0.88	0.86	8.15	1	110		6.81	
MWDIARJ1	60		2.56	1.42	0.039	0.018	109		0.88	0.97	8.15	1	120		6.78	
MWDIARJ1	60		2.56	1.42	0.039	0.017	109		0.88	0.95	8.15	1	130		6.58	
MWDIARJ1	60		2.56	1.38	0.039	0.015	109		0.88	0.87	8.15	1	140		6.39	
MWDIARJ1	60		2.56	1.37	0.039	0.015	109		0.88	1.00	8.15	1	150		6.36	
MWDIARJ1	60		2.56	1.39	0.039	0.014	109		0.88	1.20	8.15	1	170		6.23	
MWDIARJ1	60		2.56	1.33	0.039	0.014	109		0.88	1.20	8.15	1	180		6.23	
MWDIARJ1	60		2.49	2.07	0.049	0.049	110		0.84	0.76	8.13	1	0		8.14	
MWDIARJ1	60		2.49	2.15	0.049	0.035	110		0.84	0.59	8.13	1	10		7.84	
MWDIARJ1	60		2.49	2.12	0.049	0.037	110		0.84	0.59	8.13	1	20		7.44	
MWDIARJ1	60		2.49	1.92	0.049	0.023	110		0.84	0.43	8.13	1	30		7.29	
MWDIARJ1	60		2.49	1.86	0.049	0.020	110		0.84	0.43	8.13	1	40		7.18	
MWDIARJ1	60		2.49	1.80	0.049	0.020	110		0.84	0.40	8.13	1	50		7.11	
MWDIARJ1	60		2.49	1.56	0.049	0.020	110		0.84	0.60	8.13	1	60		6.92	
MWDIARJ1	60		2.49	1.62	0.049	0.018	110		0.84	0.62	8.13	1	70		6.87	
MWDIARJ1	60		2.49	1.51	0.049	0.017	110		0.84	0.49	8.13	1	80		6.85	
MWDIARJ1	60		2.49	1.47	0.049	0.017	110		0.84	0.54	8.13	1	90		6.79	
MWDIARJ1	60		2.49	1.38	0.049	0.014	110		0.84	0.83	8.13	1	100		6.71	
MWDIARJ1	60		2.49	1.39	0.049	0.014	110		0.84	0.83	8.13	1	110		6.59	
MWDIARJ1	60		2.49	1.34	0.049	0.020	110		0.84	0.97	8.13	1	120		6.53	
MWDIARJ1	60		2.49	1.35	0.049	0.021	110		0.84	0.99	8.13	1	130		6.48	
MWDIARJ1	60		2.49	1.34	0.049	0.020	110		0.84	1.20	8.13	1	140		6.39	
MWDIARJ1																

Study ID	Water	% CRW	% SPW	TOC		UV-254		Alkalinity		Turbidity		pH		Coagulant	ID	Coagulation Conditions				Coag. pH
				(mg/L)	Raw	Filter	Raw	(mg/L as CaCO ₃)	Raw	(NTU)	Raw	Filter	Raw			Acid adjusted (T/N)	Base adjusted (T/N)	Base adjusted (T/N)	Coag. pH	
MWDIA829	60			2.68	2.69	0.039	0.037	109		0.48	0.45	8.26		1					8.22	
MWDIA829	60			2.68	2.68	0.039	0.042	109		0.48	0.51	8.26		1					7.87	
MWDIA829	60			2.68	2.61	0.039	0.039	109		0.48	0.37	8.26		1					7.65	
MWDIA829	60			2.68	2.15	0.039	0.035	109		0.48	0.32	8.26		1					7.32	
MWDIA829	60			2.68	1.78	0.039	0.031	109		0.48	0.38	8.26		1					7.36	
MWDIA829	60			2.68	1.87	0.039	0.040	109		0.48	0.38	8.26		1					7.39	
MWDIA829	60			2.68	1.80	0.039	0.026	109		0.48	0.42	8.26		1					7.12	
MWDIA829	60			2.68	1.74	0.039	0.023	109		0.48	0.34	8.26		1					7.02	
MWDIA829	60			2.68	1.66	0.039	0.023	109		0.48	0.48	8.26		1					6.95	
MWDIA829	60			2.68	1.61	0.039	0.023	109		0.48	0.38	8.26		1					6.88	
MWDIA829	60			2.68	1.60	0.039	0.022	109		0.48	0.68	8.26		1					6.79	
MWDIA829	60			2.68	1.60	0.039	0.025	109		0.48	0.77	8.26		1					6.83	
MWDIA829	60			2.68	1.50	0.039	0.023	109		0.48	0.70	8.26		1					6.75	
MWDIA829	60			2.68	1.57	0.039	0.023	109		0.48	1.00	8.26		1					6.63	
MWDIA829	60			2.68	1.43	0.039	0.021	109		0.48	0.80	8.26		1					6.42	
MWDIA829	60			2.68	1.41	0.039	0.021	109		0.48	0.92	8.26		1					6.38	
MWDIA829	60			2.68	1.34	0.039	0.021	109		0.48	0.92	8.26		1					6.32	
MWDIA829	60			2.68	1.67	0.043	0.040	113		0.82	0.20	8.23		1					8.08	
MWDIA829	60			2.68	1.67	0.043	0.034	113		0.82	0.60	8.23		1					7.83	
MWDIA829	60			2.68	1.64	0.043	0.034	113		0.82	0.40	8.23		1					7.60	
MWDIA829	60			2.68	1.64	0.043	0.031	113		0.82	0.26	8.23		1					7.49	
MWDIA829	60			2.68	1.61	0.043	0.029	113		0.82	0.21	8.23		1					7.37	
MWDIA829	60			2.68	1.61	0.043	0.029	113		0.82	0.33	8.23		1					7.27	
MWDIA829	60			2.68	1.61	0.043	0.027	113		0.82	0.31	8.23		1					7.21	
MWDIA829	60			2.68	1.61	0.043	0.026	113		0.82	0.22	8.23		1					7.05	
MWDIA829	60			2.68	1.59	0.043	0.026	113		0.82	0.25	8.23		1					6.97	
MWDIA829	60			2.68	1.59	0.043	0.027	113		0.82	0.31	8.23		1					6.91	
MWDIA829	60			2.68	1.58	0.043	0.025	113		0.82	0.25	8.23		1					6.82	
MWDIA829	60			2.68	1.58	0.043	0.025	113		0.82	0.35	8.23		1					6.75	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					6.67	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					6.60	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					6.54	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					6.48	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					6.42	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					6.36	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					6.30	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					6.24	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					6.18	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					6.12	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					6.06	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					6.00	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.94	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.88	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.82	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.76	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.70	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.64	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.58	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.52	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.46	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.40	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.34	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.28	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.22	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.16	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.10	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					5.04	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.98	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.92	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.86	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.80	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.74	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.68	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.62	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.56	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.50	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.44	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.38	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.32	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.26	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.20	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.14	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.08	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					4.02	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					3.96	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					3.90	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					3.84	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					3.78	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					3.72	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					3.66	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					3.60	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1					3.54	
MWDIA829	60			2.68	1.58	0.043	0.024	113		0.82	0.23	8.23		1						

Study ID	Water		TOC		UV-254		Alkalinity		Turbidity		pH		Coagulation Conditions				
	% CRW	% SPW	(mg/L)		(1/cm)		(mg/L as CaCO3)		(NTU)		()		Coagulant ID (see above)	Dose	Acid adjusted? (Y/N) blank=N	Base adjusted? (Y/N) blank=N	Coag. pH ()
			Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.					
MWDJAR44	50		3.11	2.32	0.066	0.035	103		1.30	0.21	7.99		1	50			7.14
MWDJAR44	50		3.11	2.25	0.066	0.032	103		1.30	0.19	7.99		1	60			7.07
MWDJAR44	50		3.11	3.04	0.066	0.033	103		1.30	0.23	7.99		1	70			6.93
MWDJAR44	50		3.11	2.07	0.066	0.033	103		1.30	0.29	7.99		1	80			6.87
MWDJAR44	50		3.11	2.02	0.066	0.030	103		1.30	0.33	7.99		1	90			6.78
MWDJAR44	50		3.11	1.97	0.066	0.028	103		1.30	0.35	7.99		1	100			6.68
MWDJAR44	50		3.11	1.85	0.066	0.027	103		1.30	0.28	7.99		1	110			6.65
MWDJAR44	50		3.11	1.83	0.066	0.030	103		1.30	0.46	7.99		1	120			6.52
MWDJAR44	50		3.11	1.83	0.066	0.030	103		1.30	0.56	7.99		1	130			6.51
MWDJAR44	50		3.11	1.78	0.066	0.028	103		1.30	0.52	7.99		1	140			6.44
MWDJAR44	50		3.11	1.69	0.066	0.028	103		1.30	0.44	7.99		1	150			6.34
MWDJAR44	50		3.11	1.66	0.066	0.030	103		1.30	0.45	7.99		1	160			6.34
MWDJAR45	50		2.46	2.63		0.061	105		0.87	0.78	8.14		1	0			8.27
MWDJAR45	50		2.46	2.30		0.047	105		0.87	0.55	8.14		1	10			7.91
MWDJAR45	50		2.46	2.26		0.042	105		0.87	0.50	8.14		1	20			7.52
MWDJAR45	50		2.46	2.07		0.036	105		0.87	0.52	8.14		1	30			7.55
MWDJAR45	50		2.46	1.96		0.034	105		0.87	0.33	8.14		1	40			7.31
MWDJAR45	50		2.46	1.84		0.032	105		0.87	0.40	8.14		1	50			7.26
MWDJAR45	50		2.46	1.82		0.029	105		0.87	0.52	8.14		1	60			7.16
MWDJAR45	50		2.46	1.72		0.028	105		0.87	0.44	8.14		1	70			7.12
MWDJAR45	50		2.46	1.76		0.027	105		0.87	0.62	8.14		1	80			7.02
MWDJAR45	50		2.46	1.69		0.026	105		0.87	0.64	8.14		1	90			6.80
MWDJAR45	50		2.46	1.59		0.025	105		0.87	0.72	8.14		1	100			6.76
MWDJAR45	50		2.46	1.56		0.024	105		0.87	0.94	8.14		1	110			6.71
MWDJAR45	50		2.46	1.52		0.023	105		0.87	0.65	8.14		1	120			6.62
MWDJAR45	50		2.46	1.46		0.022	105		0.87	0.80	8.14		1	130			6.50
MWDJAR45	50		2.46	1.45		0.021	105		0.87	1.00	8.14		1	140			6.48
MWDJAR45	50		2.46	1.48		0.016	105		0.87	1.10	8.14		1	150			6.52
MWDJAR45	50		2.46	1.38		0.015	105		0.87	1.20	8.14		1	160			6.39
MWDJAR45	50		2.46	1.36		0.014	105		0.87	1.30	8.14		1	170			6.27
MWDJAR45	50		2.46	1.31		0.015	105		0.87	1.50	8.14		1	180			6.18
MWDJAR46	50		2.46	2.56	0.040	0.040	105		0.73	0.66	8.13		1	0			8.20
MWDJAR46	50		2.46	2.54	0.040	0.028	105		0.73	0.70	8.13		1	10			7.86
MWDJAR46	50		2.46	2.43	0.040	0.019	105		0.73	0.44	8.13		1	20			7.63
MWDJAR46	50		2.46	2.13	0.040	0.013	105		0.73	0.29	8.13		1	30			7.45
MWDJAR46	50		2.46	2.05	0.040	0.011	105		0.73	0.52	8.13		1	40			7.31
MWDJAR46	50		2.46	2.00	0.040	0.010	105		0.73	0.67	8.13		1	50			7.19
MWDJAR46	50		2.46	1.86	0.040	0.010	105		0.73	0.66	8.13		1	60			7.17
MWDJAR46	50		2.46	1.73	0.040	0.010	105		0.73	0.71	8.13		1	70			7.04
MWDJAR46	50		2.46	1.72	0.040	0.010	105		0.73	0.83	8.13		1	80			6.93
MWDJAR46	50		2.46	1.62	0.040	0.007	105		0.73	0.75	8.13		1	90			6.84
MWDJAR46	50		2.46	1.59	0.040	0.004	105		0.73	0.95	8.13		1	100			6.75
MWDJAR46	50		2.46	1.59	0.040	0.004	105		0.73	1.50	8.13		1	110			6.66
MWDJAR46	50		2.46	1.26	0.040	0.023	105		0.73	1.00	8.13		1	120			6.50
MWDJAR46	50		2.46	1.32	0.040	0.019	105		0.73	1.10	8.13		1	130			6.46
MWDJAR46	50		2.46	1.18	0.040	0.017	105		0.73	0.25	8.13		1	140			6.31
MWDJAR46	50		2.46	1.17	0.040	0.016	105		0.73	1.10	8.13		1	150			6.27
MWDJAR46	50		2.46	1.15	0.040	0.021	105		0.73	1.30	8.13		1	160			6.15
MWDJAR47	50		2.79	2.79	0.063	0.062	102		0.42	0.40	8.23		1	0			8.27
MWDJAR47	50		2.79	2.70	0.063	0.040	102		0.42	0.50	8.23		1	10			7.83
MWDJAR47	50		2.79	2.39	0.063	0.041	102		0.42	0.48	8.23		1	20			7.56
MWDJAR47	50		2.79	2.20	0.063	0.036	102		0.42	0.39	8.23		1	30			7.38
MWDJAR47	50		2.79	2.15	0.063	0.032	102		0.42	0.42	8.23		1	40			7.23
MWDJAR47	50		2.79	1.94	0.063	0.028	102		0.42	0.45	8.23		1	50			7.18
MWDJAR47	50		2.79	1.84	0.063	0.026	102		0.42	0.50	8.23		1	60			7.13
MWDJAR47	50		2.79	1.76	0.063	0.025	102		0.42	0.50	8.23		1	70			7.03
MWDJAR47	50		2.79	1.69	0.063	0.024	102		0.42	0.43	8.23		1	80			6.92
MWDJAR47	50		2.79	1.60	0.063	0.024	102		0.42	0.54	8.23		1	90			6.87
MWDJAR47	50		2.79	1.58	0.063	0.022	102		0.42	0.58	8.23		1	100			6.77
MWDJAR47	50		2.79	1.61	0.063	0.023	102		0.42	0.64	8.23		1	110			6.61
MWDJAR47	50		2.79	1.53	0.063	0.021	102		0.42	0.84	8.23		1	120			6.46
MWDJAR47	50		2.79	1.50	0.063	0.021	102		0.42	0.82	8.23		1	130			6.38
MWDJAR47	50		2.79	1.49	0.063	0.020	102		0.42	0.86	8.23		1	140			6.34
MWDJAR47	50		2.79	1.44	0.063	0.019	102		0.42	0.90	8.23		1	150			6.20
MWDJAR47	50		2.79	1.45	0.063	0.020	102		0.42	1.30	8.23		1	160			6.11
MWDJAR48	100		3.31	3.31	0.126		73		2.40	1.30	7.91		1	0			7.87
MWDJAR48	100		3.31	3.21	0.126	0.103	73		2.40	0.88	7.91		1	10			7.57
MWDJAR48	100		3.31	3.05	0.126	0.081	73		2.40	0.53	7.91		1	20			7.32
MWDJAR48	100		3.31	2.68	0.126	0.066	73		2.40	0.54	7.91		1	30			7.14
MWDJAR48	100		3.31	2.36	0.126	0.061	73		2.40	0.52	7.91		1	40			6.83
MWDJAR48	100		3.31	2.22	0.126	0.054	73		2.40	0.45	7.91		1	50			6.79
MWDJAR48	100		3.31	2.12	0.126	0.049	73		2.40	0.50	7.91		1	60			6.64
MWDJAR48	100		3.31	1.89	0.126	0.049	73		2.40	0.95	7.91		1	70			6.15
MWDJAR48	100		3.31	1.83	0.126	0.050	73		2.40	0.83	7.91		1	80			6.09
MWDJAR48	100		3.31	1.78	0.126	0.049	73		2.40	1.10	7.91		1	90			5.80
MWDJAR48	50		2.55	2.55	0.057	0.057	94		0.34	0.36	7.93		1	0			7.95
MWDJAR48	50		2.55	2.32	0.057	0.051	94										

Study ID	Water		TOC		UV-254		Alkalinity		Turbidity		pH		Coagulation Conditions				
	% CRW	% SPW	(mg/L)		(1/cm)		(mg/L as CaCO3)		(NTU)		(I)		Coagulant ID (see above)	Dose	Acid adjusted? (Y/N) blank=N	Base adjusted? (Y/N) blank=N	Coag. pH (I)
			Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.					
MWDJAR49		100	2.33	2.36	0.077	0.074	73		0.85	8.07			1	0			8.07
MWDJAR49		100	2.33	2.20	0.077	0.064	73		0.57	8.07			1	10			7.65
MWDJAR49		100	2.33	2.19	0.077	0.050	73		0.75	8.07			1	20			7.41
MWDJAR49		100	2.33	2.03	0.077	0.046	73		0.56	8.07			1	30			7.24
MWDJAR49		100	2.33	1.84	0.077	0.043	73		0.72	8.07			1	40			7.15
MWDJAR49		100	2.33	1.75	0.077	0.040	73		0.75	8.07			1	50			7.05
MWDJAR49		100	2.33	1.72	0.077	0.040	73		0.53	8.07			1	60			7.00
MWDJAR49		100	2.33	1.78	0.077	0.037	73		0.47	8.07			1	70			6.87
MWDJAR49		100	2.33	1.42	0.077	0.035	73		0.47	8.07			1	80			6.73
MWDJAR49		100	2.33	1.41	0.077	0.035	73		0.57	8.07			1	90			6.66
MWDJAR49		100	2.33	1.54	0.077	0.030	73		0.56	8.07			1	100			6.58
MWDJAR49		100	2.33	1.31	0.077	0.028	73		0.60	8.07			1	110			6.45
MWDJAR49		100	2.33	1.30	0.077	0.011	73		0.45	8.07			1	120			6.38
MWDJAR49		100	2.33	1.25	0.077	0.029	73		0.60	8.07			1	130			6.23
MWDJAR49		100	2.33	1.20	0.077	0.028	73		0.65	8.07			1	140			6.14
MWDJAR5	100		2.37	2.40	0.048	0.048	131		0.76	8.23			1	0			8.23
MWDJAR5	100		2.37	2.27	0.048	0.043	131		0.76	8.23			1	10			7.88
MWDJAR5	100		2.37	2.19	0.048	0.038	131		0.76	8.23			1	20			7.77
MWDJAR5	100		2.37	2.22	0.048	0.036	131		0.76	8.23			1	30			7.66
MWDJAR5	100		2.37	2.07	0.048	0.033	131		0.76	8.23			1	40			7.52
MWDJAR5	100		2.37	1.96	0.048	0.029	131		0.76	8.23			1	50			7.44
MWDJAR5	100		2.37	1.94	0.048	0.028	131		0.76	8.23			1	60			7.36
MWDJAR5	100		2.37	1.84	0.048	0.026	131		0.76	8.23			1	70			7.25
MWDJAR5	100		2.37	1.77	0.048	0.025	131		0.76	8.23			1	80			7.16
MWDJAR5	100		2.37	1.75	0.048	0.024	131		0.76	8.23			1	90			7.05
MWDJAR5	100		2.37	1.68	0.048	0.015	131		0.76	8.23			1	100			7.06
MWDJAR5	100		2.37	1.65	0.048	0.015	131		0.76	8.23			1	110			6.97
MWDJAR50		100	3.90	4.45	0.110	0.109	77		1.7	8.00			1	0			8.00
MWDJAR50		100	3.90	3.69	0.110	0.072	77		1.7	7.99			1	10			7.44
MWDJAR50		100	3.90	3.17	0.110	0.049	77		1.7	7.99			1	20			7.15
MWDJAR50		100	3.90	2.81	0.110	0.037	77		1.7	7.98			1	30			6.99
MWDJAR50		100	3.90	2.38	0.110	0.032	77		1.7	8.01			1	40			6.92
MWDJAR50		100	3.90	2.25	0.110	0.029	77		1.7	8.00			1	50			6.89
MWDJAR50		100	3.90	2.16	0.110	0.024	77		1.7	8.00			1	60			6.66
MWDJAR50		100	3.90	2.06	0.110	0.020	77		1.7	8.00			1	70			6.45
MWDJAR50		100	3.90	1.99	0.110	0.020	77		1.7	8.00			1	80			6.31
MWDJAR50		100	3.90	2.00	0.110	0.021	77		1.7	8.00			1	90			6.14
MWDJAR50		100	3.90	2.03	0.110	0.018	77		1.7	8.00			1	100			5.93
MWDJAR50		100	3.90	1.80	0.110	0.020	77		1.7	8.00			1	110			5.70
MWDJAR51		100	3.09	3.17	0.097	0.103	81		0.85	7.80			1	0			7.86
MWDJAR51		100	3.09	2.94	0.097	0.077	81		0.85	7.80			1	10			7.58
MWDJAR51		100	3.09	3.28	0.097	0.072	81		0.85	7.80			1	20			7.58
MWDJAR51		100	3.09	2.97	0.097	0.066	81		0.85	7.80			1	30			7.14
MWDJAR51		100	3.09	2.42	0.097	0.054	81		0.85	7.80			1	40			7.06
MWDJAR51		100	3.09	2.23	0.097	0.049	81		0.85	7.80			1	50			7.00
MWDJAR51		100	3.09	2.55	0.097	0.051	81		0.85	7.80			1	60			6.97
MWDJAR51		100	3.09	2.32	0.097	0.044	81		0.85	7.80			1	70			6.77
MWDJAR51		100	3.09	2.31	0.097	0.040	81		0.85	7.80			1	80			6.66
MWDJAR51		100	3.09	2.33	0.097	0.039	81		0.85	7.80			1	90			6.57
MWDJAR51		100	3.09	2.08	0.097	0.036	81		0.85	7.80			1	100			6.43
MWDJAR51		100	3.09	1.94	0.097	0.040	81		0.85	7.80			1	110			6.35
MWDJAR51		100	3.09	1.74	0.097	0.038	81		0.85	7.80			1	120			6.23
MWDJAR51		100	3.09	1.91	0.097	0.035	81		0.85	7.80			1	130			6.25
MWDJAR52		100	2.78	2.94		0.061			0.78	7.72			1	0			7.91
MWDJAR52		100	2.78	2.88		0.051			0.78	7.72			1	10			7.70
MWDJAR52		100	2.78	2.40		0.051			0.78	7.72			1	20			7.33
MWDJAR52		100	2.78	2.09		0.048			0.78	7.72			1	30			7.14
MWDJAR52		100	2.78	1.95		0.040			0.78	7.72			1	40			7.11
MWDJAR52		100	2.78	1.88		0.034			0.78	7.72			1	50			6.92
MWDJAR52		100	2.78	1.75		0.031			0.78	7.72			1	60			6.88
MWDJAR52		100	2.78	1.64		0.028			0.78	7.72			1	70			6.84
MWDJAR52		100	2.78	1.52		0.026			0.78	7.72			1	80			6.71
MWDJAR52		100	2.78	1.49		0.025			0.78	7.72			1	90			6.65
MWDJAR52		100	2.78	1.47		0.025			0.78	7.72			1	100			6.58
MWDJAR52		100	2.78	1.43		0.024			0.78	7.72			1	110			6.45
MWDJAR52		100	2.78	1.36		0.023			0.78	7.72			1	120			6.34
MWDJAR52		100	2.78	1.29		0.023			0.78	7.72			1	130			6.25
MWDJAR52		100	2.78	1.34		0.024			0.78	7.72			1	140			6.07
MWDJAR53		100	2.25	2.40	0.065	0.066	79		1.10	7.98			1	0			7.98
MWDJAR53		100	2.25	2.24	0.065	0.046	79		1.10	7.98			1	10			7.58
MWDJAR53		100	2.25	1.98	0.065	0.031	79		1.10	7.98			1	20			7.33
MWDJAR53		100	2.25	2.06	0.065	0.021	79		1.10	7.98			1	30			7.13
MWDJAR53		100	2.25	1.59	0.065	0.017	79		1.10	7.98			1	40			7.07
MWDJAR53		100	2.25	1.75	0.065	0.016	79		1.10	7.98			1	50			6.97
MWDJAR53		100	2.25	1.45	0.065	0.013	79		1.10	7.98			1	60			6.69
MWDJAR53		100	2.25	1.38	0.065	0.009	79		1.10	7.98			1	70			6.61
MWDJAR53		100	2.25	1.35	0.065	0.008	79		1.10	7.98			1	80			6.54
MWDJAR53		100	2.25	1.43	0.065	0.007	79		1.10	7.98			1	90			6.46
MWDJAR53		100	2.25	1.21	0.065	0.006	79		1.10	7.98			1	100			6.33
MWDJAR53		100	2.25	1.19	0.065	0.006	79		1.10	7.98							

Study ID	Water		TOC		UV-254		Alkalinity		Turbidity		pH		Coagulation Conditions				
	% CRW	% SPW	(mg/L)		(1/cm)		(mg/L as CaCO3)		(NTU)		()		Coagulant ID	Dose	Acid adjusted? (Y/N)	Base adjusted? (Y/N)	Coag. pH ()
			Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.	Raw	Filt.					
MWDJAR54	100		2.92	1.30	0.087	0.014	72		0.52	0.62	7.87		1	120			6.12
MWDJAR54	100		2.92	1.27	0.087	0.013	72		0.52	0.68	7.87		1	130			6.08
MWDJAR54	100		2.92	1.22	0.087	0.014	72		0.52	0.81	7.87		1	140			5.93
MWDJAR54	100		2.92	1.25	0.087	0.014	72		0.52	0.98	7.87		1	150			5.69
MWDJAR54	100		2.92	1.23	0.087	0.021	72		0.52	1.30	7.87		1	160			5.51
MWDJAR55	100		2.68	2.65	0.086	0.083	62		0.72	0.55	7.82		1	0			7.77
MWDJAR55	100		2.68	2.43	0.086	0.061	62		0.72	0.42	7.82		1	10			7.52
MWDJAR55	100		2.68	2.24	0.086	0.051	62		0.72	0.74	7.82		1	20			7.35
MWDJAR55	100		2.68	2.00	0.086	0.040	62		0.72	0.34	7.82		1	30			7.18
MWDJAR55	100		2.68	1.76	0.086	0.036	62		0.72	0.29	7.82		1	40			7.12
MWDJAR55	100		2.68	1.76	0.086	0.032	62		0.72	0.30	7.82		1	50			7.20
MWDJAR55	100		2.68	1.58	0.086	0.030	62		0.72	0.28	7.82		1	60			7.08
MWDJAR55	100		2.68	1.40	0.086	0.029	62		0.72	0.24	7.82		1	70			6.97
MWDJAR55	100		2.68	1.45	0.086	0.027	62		0.72	0.25	7.82		1	80			6.84
MWDJAR55	100		2.68	1.40	0.086	0.024	62		0.72	0.31	7.82		1	90			6.67
MWDJAR55	100		2.68	1.34	0.086	0.023	62		0.72	0.25	7.82		1	100			6.50
MWDJAR55	100		2.68	1.47	0.086	0.024	62		0.72	0.74	7.82		1	110			6.45
MWDJAR55	100		2.68	1.31	0.086	0.024	62		0.72	0.44	7.82		1	120			6.20
MWDJAR55	100		2.68	1.34	0.086	0.021	62		0.72	0.63	7.82		1	130			5.95
MWDJAR55	100		2.68	1.33	0.086	0.022	62		0.72	0.50	7.82		1	140			5.83
MWDJAR55	100		2.68	1.30	0.086	0.022	62		0.72	0.72	7.82		1	150			5.52
MWDJAR55	100		2.68	1.32	0.086	0.021	62		0.72	0.72	7.82		1	160			5.30

Study ID				Disinfection By-products				Coagulation Conditions				
	ered			TTHM		HAA5		Coagulant	Dose	Acid	Base	Coag.
	mmoni	bubation t	Residual	(µg/L)		(µg/L)		ID		adjusted?	adjusted?	pH
	dose	(h)		Raw	Filt.	Raw	Filt.	(see above)		(Y/N)	(Y/N)	(deg. C)
	g NH3-N	chlorine	(mg Cl2/L)									
MWDOP4				67.4		29.4		1	20	Y		7.17
MWDOP4				62.7		<28.9		1	20	Y		7.11
MWDOP4				54.9		<22.3		1	20	Y		6.34
MWDOP4				49.9		21.0		1	20	Y		6.40
MWDOP4				53.1		20.9		1	20	Y		5.52
MWDOP4				52.2		22.4		1	20	Y		5.71
MWDOP4				62.1		23.8		1	30	Y		7.26
MWDOP4				63.5		<24.7		1	30	Y		7.05
MWDOP4				53.0		<21.1		1	30	Y		6.26
MWDOP4				53.8		<20.3		1	30	Y		6.50
MWDOP4				48.1		<17.8		1	30	Y		6.23
MWDOP4				46.7		<21.5		1	30	Y		5.43
MWDOP4				56.4		24.9		1	40	Y		6.97
MWDOP4				57.1		25.3		1	40	Y		7.24
MWDOP4				52.4		<21.5		1	40	Y		6.30
MWDOP4				43.9		<18.7		1	40	Y		6.19
MWDOP4				45.9		<18.0		1	40	Y		5.65
MWDOP4				46.1		<18.6		1	40	Y		5.74
MWDOP4				43.6		<15.8		1	40	Y		5.42
MWDOP5				22.2		11.7		1	10	Y		5.88
MWDOP5				22.0		14.7		1	20	Y		7.58
MWDOP5				18.7		11.1		1	20	Y		6.89
MWDOP5				16.6		9.5		1	20	Y		6.50
MWDOP5				17.4		9.2		1	20	Y		5.75
MWDOP5				17.5		<10.6		1	20	Y		5.31
MWDOP5				18.7		9.8		1	40	Y		6.90
MWDOP5				16.3		9.2		1	40	Y		5.53

[illegible]

[illegible]

[illegible]

Page 1 of 3

Page 2 of 3

C-0310

DELTA WATER QUALITY AND TREATMENT LIMITATIONS FOR CURRENTLY AVAILABLE ADVANCED WATER TREATMENT TECHNOLOGY¹

Drinking water regulations must balance health risks from microbial and chemical contaminants. Chlorination, the traditional method of controlling microbial risks, reacts with naturally occurring matter in water to produce Disinfection By-products (DBPs), which are suspected cancer-causing compounds. Pathogens such as viruses, *Giardia* and *Cryptosporidium* pose acute, short-term gastrointestinal health effects which, in the case of *Cryptosporidium*, can be life-threatening to those with weakened immune systems including infants and the elderly. As depicted in Figure 1, the ability to balance risks from pathogens and DBPs is controlled by a combination of source water quality and practical limitations of treatment technology.

EPA is currently developing parallel regulations for controlling DBPs (Stage 1 and 2 of the DBP Rule) and waterborne disease agents (Interim and Enhanced Surface Water Treatment Rule). Both of these regulations will require most water utilities to implement newer, more expensive treatment technologies. Enhanced coagulation and ozonation are considered best available technologies for complying with these regulations. More advanced treatment technologies such as filtration membranes and granulated activated carbon are extremely expensive and have potential environmental implementation ramifications. Given this, it is important to know the required source water quality which will allow current best available technology to perform within expected future drinking water standards. With the Delta providing the source water for all or a portion of the water supply for two-thirds of the state's population, its quality will be critical in future water treatment management decisions.

Traditional water treatment technology of filtration and disinfection with chlorine was acceptable until regulations requiring a reduction in DBPs forced many entities to begin

C-1

¹ Prepared by California Urban Water Agencies

DRAFT 12/18/96

reducing chlorine contact time or use a combination of ammonia and chlorine (chloramines) which reduced DBPs. However, these methods cannot meet expected Stage 1 requirements for *Giardia*, DBPs, and total organic carbon (TOC) removal when using Delta water. Therefore, enhanced coagulation or ozone is required. Although enhanced coagulation, in combination with free chlorine, can control DBPs and *Giardia*, chlorination is ineffective against *Cryptosporidium*. Ozone disinfection is also very effective for controlling *Giardia* while limiting the formation of many DBPs, and can even disinfect for *Cryptosporidium*. However, as greater quantities of ozone are required for disinfection of *Cryptosporidium*, disinfection by-products of the ozonation process occur. Principle among these is the compound bromate, a DBP to be regulated in the DBP rule. Bromate is formed by the reaction of ozone with bromide, with higher levels of either constituent producing more bromate. Delta waters commonly contain bromide, borne by seawater mixing with Delta inflow on the tidal cycle.

Figure 2 depicts increasing Delta water quality constraints as drinking water regulations become more stringent. For example, assuming a 90-percent inactivation of *Giardia* (1 log), the water quality from the Delta would need to be 3.0-4.0 mg/L for Total Organic Carbon and the bromide concentration would have to be in the range of 50-250 $\mu\text{g/L}$, depending upon the treatment technique. As additional disinfection requirements (2-log *Giardia*) are implemented, water quality required to allow ozone to meet these requirements must improve: TOC <3.0 mg/L and bromide <50-150 $\mu\text{g/L}$. Finally, if inactivation of *Cryptosporidium* is required, then ozonation is the only effective option prior to implementation of membranes and GAC and would require a very low bromide concentration (<50 $\mu\text{g/L}$) to comply with the anticipated standard for bromate.

Figure 1


Balancing Disinfection and Chemical By-Products

➤ Disinfection

- *Giardia*
- Viruses
- *Cryptosporidium*

➤ Disinfection By-Products

- T H Ms
- H A As
- Bromate



➤ Treatment

- Chlorination/chloramination
- Ozonation
- Enhanced coagulation
- G A C
- Membranes

➤ Source water quality

FIGURE 2

**DELTA EXPORT WATER QUALITY AND TREATMENT CONDITIONS
REQUIRED TO MEET REGULATORY SCENARIOS**

	EXISTING OR PROPOSED REGULATIONS				DISINFECTION ASSUMPTION	TREATMENT**	DELTA WATER QUALITY CRITERIA
	THMs* (ug/L)	HAAs* (ug/L)	BROMATE (ug/L)	TOC* (mg/L)			
1979 THM Standard	100	None	None	None	None	Chlorination/Chloramination	None
Surface Water Treatment Rule SWTR (1993)	-	-	-	-	0.5 log <i>Giardia</i>	Prechlorinated/Conventional	Br < app. 400 ug/L****
Stage 1 DBP Rule/Interim SWTR (2001-2003)	80	60	5 or 10	up to 50% reduction	0.5 log <i>Giardia</i>	Enhanced Coagulation or Ozonation	not analyzed
Stage 2 DBP Rule/ Enhanced SWTR (2003-2005)	40	30	5	up to 50% reduction	1 log <i>Giardia</i>	Enhanced Coagulation or Ozonation	TOC 3-4 mg/L Br <50-250 ug/L
Stage 2 DBP Rule/ Enhanced SWTR (2003-2005)	40	30	5	up to 50% reduction	2 log <i>Giardia</i>	Enhanced Coagulation or Ozonation	TOC <3 mg/L Br 50-150
Stage 2 DBP Rule/ Enhanced SWTR (2003-2005)	40	30	5	up to 50% reduction	1 log <i>Cryptosporidium</i>	Ozonation***	TOC <3.0 mg/L Br <50 ug/L

*THMs = Trihalomethanes, HAAs = Haloacetic acids, TOC = total organic carbon

** Treatment assumes conventional filtration for ozone, enhanced coagulation options

*** Assumes ozone at pH 6.5

****Based on results at Metropolitan Water District

C-031083